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Resumo 
Das suas quatro cavidades à sua síncrona rede elétrica, o coração foi 
perfeitamente projetado para servir de interface entre cada órgão presente no 
corpo humano. Devido à sua complexidade, as doenças cardiovasculares 
englobam também um grande conjunto de manifestações clínicas incluindo 
miocardites, hipertensão arterial, defeitos congénitos cardíacos e doenças 
isquémicas. Muitas destas patologias traduzem-se geralmente na perda de 
tecido cardíaco funcional e por outro lado pela formação de tecido fibrótico não 
funcional. Similarmente ao que ocorre nos países desenvolvidos, em Portugal 
também as doenças cardiovasculares continuam a ser uma das maiores 
causas de morbidade e mortalidade. 
Devido à limitada capacidade regenerativa do coração e ao facto das terapias 
existentes para tratar doenças cardiovasculares serem ineficientes ou 
implicarem enormes riscos para o paciente, é urgente desenvolver novas 
terapias mais eficazes. Nesse sentido, o uso de células multi e pluripotentes 
tem contribuído na última década para um franco avanço nesta área. Muitos 
ensaios clínicos têm sido feitos, ou decorrem ainda, onde se avalia a 
capacidade regenerativa de células estaminais de diferentes origens na 
reposição dos tecidos cardíacos danificados. Além disto pensa-se que certos 
nichos de células progenitoras de cardiomiócitos residentes no coração adulto 
possam representar um mecanismo endógeno de regeneração. De modo a 
explorar este mecanismo tem-se recorrido a técnicas de isolamento destas 
células para transplante em doentes cardíacos. No entanto, até agora as 
melhorias evidenciadas por essas terapias celulares parecem estar associadas 
a efeitos parácrinos que as células transplantadas exercem sobre os tecidos 
envolventes, em detrimento da sua implantação no tecido danificado e 
consequente diferenciação em novo tecido cardíaco. Em paralelo às terapias 
celulares tem-se feito um esforço para desenvolver patches e scaffolds que 
possam complementar estas terapias por facilitar o homing de células 
transplantadas ao constituírem uma matriz onde estas células possam ser 
envolvidas e desempenhar a sua função.  
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Outra alternativa ao uso de células estaminais para uso em terapias de 
regeneração cardíaca é o uso de células já diferenciadas com identidade 
semelhante à do tecido a ser substituído. No caso do miocárdio, será 
potencialmente interessante o uso de cardiomiócitos como fonte em 
transplantes para a regeneração do tecido danificado. Tal abordagem é 
especialmente interessante visto terem sido identificadas no coração 
populações de novos cardiomiócitos derivados de cardiomiócitos já existentes, 
que contribuem para o turnover normal do miocárdio. No entanto, para explorar 
este mecanismo é necessário criar e otimizar protocolos eticamente aceitáveis 
para experimentação humana de derivação em grande escala de 
cardiomiócitos a partir de células pluripotentes. Tal objetivo pode ser alcançado 
através do uso de fatores segregados que possam ser utilizados para estimular 
o potencial cardiogénico das células pluripotentes.  
A procura de genes envolvidos na cardiogénese têm-se tornado cada vez mais 
importante com o objetivo de identificar potenciais fatores que possam modular 
este processo biológico quer in vitro como in vivo. De facto, é possível modelar 
in vitro com grande rigor os estadios iniciais da cardiogénese através da 
diferenciação de células estaminais. Tal como ocorre in vivo, a especificação 
das linhagens cardiovasculares in vitro implica uma transição para populações 
de células progenitoras cardíacas com potencial de diferenciação cada vez 
mais restrito e específico. Começando num estado de pluripotência, durante a 
sua diferenciação estas especificam-se em mesoderme cardíaca e 
posteriormente em células de todas as outras linhagens cardíacas. Para 
monitorizar o seguimento deste processo biológico e para assegurar o correto 
comprometimento nas várias linhagens cardíacas recorre-se à expressão 
génica de marcadores genéticos específicos para cada linhagem esperada em 
cada ponto específico de tempo. Através desta monitorização é possível 
identificar células de mesoderme cardíaca pela expressão dos genes Mesp-1 e 
Isl-1 a dia 4 de diferenciação das células estaminais, e também diferentes 
populações de células progenitoras cardíacas pela expressão concomitante de 
genes como Isl-1 e Nkx2.5 em dias posteriores. Assim é possível estabelecer 
em laboratório um modelo fidedigno e manipulável para se estudar a 
cardiogénese. 
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Num rastreio génico efetuado pelo nosso laboratório em células progenitoras 
cardíacas de galinha com expressão do marcador Nkx2.5, foram identificados 
genes não caracterizados, mas com um potencial envolvimento na 
cardiogénese. Um destes novos genes identificados foi o collagen and calcium 
binding EGF domains 1 ou Ccbe1. Na literatura, é possível hoje ver que em 
modelos animais knockout para este gene, um outro processo biológico é 
afetado i.e. a linfangiogénese. Estes animais apresentam uma total ausência 
de vasos linfáticos. Este fenótipo deve-se em parte ao papel já identificado que 
o CCBE1 tem na maturação do fator pro-linfangiogénico VEGF-C. Em humanos 
a síndrome de Hennekam (associado também a mutações em CCBE1), é 
caracterizada pela existência de uma rede linfática disfuncional fazendo com 
que estes apresentem um edema generalizado. Não obstante estes estudos, 
recentemente verificou-se em ratinho e galinha a expressão deste gene nas 
regiões embrionárias que dão origem ao coração, sugerindo assim também um 
potencial papel neste processo. De facto, trabalho efectuado no nosso 
laboratório veio a demonstrar que o silenciamento deste gene em galinha leva 
ao desenvolvimento de defeitos cardíacos incompatíveis com a vida, 
associados a uma redução da proliferação das células cardiacas. Também, em 
ratinhos knockout para este gene é possível identificar um miocárdio 
subdesenvolvido pelo estreitamento da camada compacta do miocárdio 
também associado a problemas na proliferação. Assim, no presente trabalho 
propusemo-nos a estudar mais detalhadamente o envolvimento deste gene nos 
estadios iniciais da cardiogénese. Como este gene codifica para uma proteína 
secretada, a verificar-se um importante papel na cardiogénese, a sua 
manipulação como um fator de crescimento torna-se de grande interesse 
visando a otimização de protocolos para derivação de cardiomiócitos.  
Para estudar os estadios iniciais da cardiogénese recorremos ao uso de uma 
linha de células estaminais duplamente transgénica que nos permite 
acompanhar o processo de diferenciação para linhagens cardíacas pois 
expressam a proteína fluorescente GFP sob o controlo do promotor de Nkx2.5 
e a proteína fluorescente dsRed sob um promotor específico de cardiogénese 
de Mef2c. Assim pode-se confirmar que é possível obter células progenitoras 
cardíacas in vitro correspondentes aos estadios iniciais do desenvolvimento do 
coração de ratinho. De seguida analisámos o padrão de expressão de Ccbe1 e 
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verificou-se que coincide com o aparecimento da expressão dos marcadores 
genéticos cardíacos, mostrando que in vitro a sua expressão ocorre aquando 
da especificação das células para as linhagens cardíacas. Posteriormente 
gerámos duas linhas estáveis de células estaminais com silenciamento de 
Ccbe1 para avaliar o seu impacto na cardiogénese. Os resultados demonstram 
que ao diferenciar estas células em agregados 3D conhecidos como corpos 
embrióides (nome dado devido à sua semelhança física e funcional com um 
embrião nos estadios iniciais do desenvolvimento), estas células são incapazes 
de se especificar em mesoderme cardíaca pois apresentam a expressão de 
Mesp-1 e Isl-1 reduzida. Em paralelo com estes resultados, foi possível verificar 
que os corpos embrióides gerados a partir de células estaminais com 
silenciamento de Ccbe1 apresentam um tamanho muito reduzido. Este defeito 
é devido não a um aumento da morte celular mas sim a um défice na 
proliferação das células estaminais silenciadas. Estes defeitos na proliferação 
estão de acordo com outros estudos efetuados pela nossa equipa, em que 
fibroblastos embrionários derivados de ratinhos knockout apresentam grandes 
problemas na proliferação. Adicionalmente, em embriões de galinha foi 
verificado necessidade de Ccbe1 para a correta proliferação de células 
precursoras cardíacas para formar o tubo cardíaco. Em conjunto, estes 
resultados demonstram que CCBE1 tem um papel importante em proliferação. 
Tais resultados são corroborados por experiências onde foi feita a adição de 
CCBE1 recombinante ao meio de cultura e se observou a recuperação parcial 
dos corpos embrióides silenciados. Apesar das dificuldades em produzir 
quantidades elevadas desta proteína recombinante, os resultados indicam que 
CCBE1 foi capaz de aumentar a proliferação dos corpos embrióides 
silenciados. No entanto, as células demonstram-se incapazes de se especificar 
em mesoderme cardíaca, sugerindo que para além deste papel que Ccbe1 tem 
em proliferação, o seu papel na cardiogénese é independente deste 
mecanismo.  
Conclui-se assim que Ccbe1 é indispensável para a especificação das células 
em diferenciação em mesoderme cardíaca. Para vir a ser utilizado no futuro 
como fator de crescimento em células estaminais em diferenciação, para 
derivar grandes quantidades de células cardíacas, é necessário desenvolver 
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ainda mais estudos que permitam ultrapassar as limitações associadas à sua 
produção e à sua bioatividade. 
Paralelamente a estes estudos, uma outra parte do meu trabalho incidiu numa 
colaboração com uma equipa de bioinformática, na qual nos propusemos a 
analisar o transcriptoma de diferentes tipos de células progenitoras cardíacas. 
O objetivo desta análise seria primariamente identificar através de 
sequenciação RNA novas isoformas de genes envolvidos na cardiogénese, e 
adicionalmente identificar novos genes não caracterizados com potencial 
impacto na cardiogénese. Para tal utilizámos a linha de células estaminais 
duplamente transgénica já referida, da qual isolámos diferentes populações de 
células progenitoras cardíacas em dias de diferenciação diferentes. 
Conseguimos analisar o dataset resultante utilizando algumas ferramentas 
bioinformáticas, que nos permitiu construir uma lista de genes potencialmente 
envolvidos em cardiogénese ainda não caracterizados. Deste trabalho resultam 
alguns genes que merecerão um estudo funcional mais detalhado visto 
estarem claramente expressos nas regiões embrionárias cardiogénicas. 
 
Palavras-chave: cardiogénese; cardiomiócitos; diferenciação de células 
estaminais; terapia regenerativa; doenças cardiovasculares; Ccbe1; 
sequenciação de RNA. 
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Abstract 
The identification and use of new growth factors to stimulate the cardiogenic 
potential of pluripotent cells is a safe and alternative approach to develop cell 
therapies to address the limited regenerative capacity of the heart. 
Collagen and calcium binding EGF domains 1 (Ccbe1) was firstly identified in 
our laboratory, which encodes for a secreted protein with potential involvement 
in cardiogenesis. Knockout animal models for this gene and humans with 
mutations in CCBE1, have lymphangiogenic defects, resulting in the absence of 
lymphatic vessels. This is in part due to the known described role that CCBE1 
has in the processing of the pro lymphangiogenic factor VEGF-C. However, 
Ccbe1 is also expressed in the embryonic cardiogenic regions of both mouse 
and chick and in fact, silencing this gene in chick embryos leads to the 
development of heart defects incompatible with life. Noteworthy, knockout mice 
show an underdeveloped myocardium. The objective of the present work is to 
perform a detailed study of the involvement of this gene in the early stages of 
cardiogenesis. 
The results demonstrate that silencing the expression of Ccbe1 or blocking 
CCBE1 in differentiating stem cells, impairs their specification towards cardiac 
mesodermal lineages. Additionally, we found that differentiating Ccbe1 KD 
ESCs have a reduced proliferation rate that leads to smaller EBs. In agreement 
with this result, when supplementing the differentiating Ccbe1 KD ESCs lines 
with recombinant CCBE1, we were able to partially rescue the size of the EBs, 
but the expression of the cardiac mesoderm markers remained downregulated. 
These data suggest that those defects are independent from each other, but are 
intimately related to the disruption of Ccbe1, placing CCBE1 as a direct 
regulator of cell proliferation and cardiac mesoderm specification during ESC 
differentiation.  
 
Keywords: Cardiogenesis; cardiomyocytes; ESCs diferentiation; cardiovascular 
disease; Ccbe1; RNA sequencing.  
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1. Definition and prevalence of cardiovascular disease 
From its four different chambers to its synchronous electric network, the heart is 
perfectly engineered to act as an interface to every single different system 
present in human organism. Due to heart’s complexity, cardiovascular disease 
can enclose a vast set of cardiac manifestations including inflammatory heart 
disease, hypertensive heart disease, congenital heart disease and ischemic 
heart disease. Despite all of these different etiologies cardiovascular disease 
can have, the ultimate outcome is with no exception very similar – ectopic 
cardiac function that ultimately leads to scarred and/or dead heart tissue. For 
example, in ischemic heart disease, coronary insufficiency results in myocardial 
infarction, and ultimately cardiomyocyte loss.  
In Portugal cardiovascular disease is the leading cause of morbidity and 
mortality in the adult population, being it a proper reflection of that what occurs 
in developed countries (INE 2013; Jessup and Brozena, 2003).  
1.1. Limited cardiac regeneration capacity 
As the heart has a very limited regeneration capacity, all injuries caused in heart 
tissue represent a major medical challenge when it comes to the replacement of 
the lost tissue. Looking at the major component of the heart the myocardium 
after an ischemic infarction, contractile myocardial tissue is replaced by non-
contractile scar tissue (Cao et al., 2008). Cardiac transplantation has been the 
standard therapy to overcome a conditioned poorly functioning heart, however 
is limited by the number of available donors (Jing et al., 2008) and to a series of 
associated risks such as immunoreactivity, organ rejection and the side effects 
of immunosuppressive therapies (NHLBI, 2012). 
2. Current strategies to regenerate the heart 
With the advancement of tissue regeneration technologies on the past two 
decades, a different light started to be shed on cardiac regeneration, setting in 
motion the investigation on what could be the real potential of such therapies in 
restoring lost tissues in damaged hearts. From where we stand now, a lot of 
progresses have been made in such therapies, as I am going to explain in more 
detail on the next sections. 
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2.1. Pluripotent and multipotent cell-based therapies in cardiac 
repair 
The ultimate goal for any cell-based therapy is to regenerate diseased or 
damaged tissues or cells by the use of autologous, allogenic or xenogenic cells. 
In the case of the latter two, it would be optimal that these cells lacked 
immunogenicity in order for the cells to engraft the injured area without 
triggering an immunological response that could lead to cell rejection and local 
inflamation. However, life-long lasting immunosupressive therapies often will 
have to be combined with the use of those cells. On the other hand, autologous 
cell-based therapies is the ultimate optimal option as this major limitation would 
be overcome, withdrawing the need to use immunosupressive therapies. Cell-
based therapies can comprise diverse delivery strategies, in order to deliver 
cells into the injured sites or areas, such as systemic intravenous administration 
or, more specifically, in situ administration, eg. intracoronary administration in 
myocardial repair strategies (Hastings et al, 2014). 
In cardiac repair approaches, it was thought that pluripotent or multipotent stem 
cells could drive regeneration by differentiating and repopulating the damaged 
tissue in the heart. Hence, types of cells that preserved to some extent a 
pluri/multipotent capacity have been so far tested aiming this goal. In fact, there 
are already excellent reviews about the most various cell types explored in 
order to develop the most efficient therapy, that are currently on phase I and II 
clinical trials (Boyle et al., 2006; Sanganalmath and Bolli, 2013; Aguirre et al., 
2013; Hastings et al., 2014). Accordingly, a meta-analysis from 50 different 
clinical studies confirmed that overall local benefit was significant, as ejection 
fraction increased by 3.96 % for a period of at least 2 years in patients with or 
without myocardial infarction; while present infarct size was reduced by more 
than 4% (Jeevanantham et al., 2012). 
Most of these cell-based therapies rely on the cardiogenic potential that some 
cell niches have been identified to preserve in adult mammalians (Kim et al., 
2015). Apart from the pluripotent potential of embryonic stem cells (ESCs; 
discussed in more detail on section 4), other cell niches that have been 
manipulated aiming towards the same goal include mesenchymal stem cells 
(MSCs), adipocyte-derived stem cells (ASCs), bone marrow-derived 
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mesenchymal stem cells (BMMSCs) and induced pluripotent stem cells 
(iPSCs). Although iPSCs have similar differentiation potential as ESCs, one of 
the major advantages its cell-based therapies offer is that they are patient-
specific, meaning that there is a reduced chance of transplant rejection, and are 
also easy to generate (e.g. with a patient fibroblast sample). In addition, the 
other cell lines used can only differentiate into more restricted fates as they are 
multipotent instead of pluripotent like ESCs and iPSCs (Takahashi and 
Yamanaka, 2006; Gnecchi and Melo, 2009; Nardi and Meireles, 2006; Zuk et 
al., 2001). However, on the other hand due to their pluripotent state, ESCs and 
iPSCs have higher tumorigenicity than multipotent or even differentiated cells.  
Interstingly, the main evidences so far in large mammals and on the ongoing 
clinical trials have related the benefits of such therapies more likely to a 
paracrine effect that transplanted cells exert on the surrounding cells rather than 
to in situ differentiation into new tissue, as initially envisaged (Boyle et al., 2006; 
Sanganalmath and Bolli, 2013; Aguirre et al., 2013). 
2.2. Adult cells-based therapies 
Another promising cell population that has been described to have regeneration 
potential is adult cardiac progenitor cells (CPCs).  Despite the heterogeneity, 
and-nonconsensual origin of CPCs, it has been described that the Sca-1+ 
compartment of CPCs can contribute, even though at a low rate, to myocardial 
turnover (extensively reviewed in Valente et al., 2014). Indeed, a clinical trial 
using cardiospheres-derived Sca1+ cells has shown that these cells contribute 
to cardiac improvements after myocardial infarction. In this trial it was shown 
reductions in scar mass (p=0·001), increments in viable heart mass (p=0·01) 
and regional contractility (p=0·02), and regional systolic wall thickening 
(p=0.015). However, there were not identified improvements in the left 
ventricular ejection fraction, the most-expected functional outcome when 
regenerating the myocardium (Makkar et al., 2012). Therefore there is a need to 
try to understand at the single cell level, the differences that may exist between 
the overall Sca1+ CPCs and other Sca1+ stromal cells, such as cardiac 
fibroblasts (CD90+). It is not clear which cell population, nor to which extent, are
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Figure 1.1 – Schematic representation for the potential uses of cardiovascular 
progenitors and cardiomyocytes in cardiac regenerative therapies. Deriving 
cardiovascular progenitors from multipotent cells or pluripotent stem cells using growth 
factors, is a major step for ultimately derive large amounts of cardiomyocytes. On the 
other hand isolating and purifying adult CPCs populations or cardiovascular progenitors 
can be transplanted directly into an injured myocardium, or alternatively, be expanded 
into larger numbers, followed by further differentiation into functional cardiomyocytes. 
Derived patient-specific cardiomyocytes can be used in various cellular assays, several 
examples of which are shown, to study and develop therapies for a variety of 
cardiovascular disorders, including cardiomyopathy, electrophysiological (EP) disorders, 
and congenital defects. One major goal the production of cardiomyocytes aims is to be 
used in developing efficient cardiomyocyte transplantation techniques for myocardial 
regeneration. 
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these different Sca1+ cell populations contributing for cardiac regeneration 
(Valente et al., 2014). Being confirmed the existence of the multipotent 
compartment of cells amongst Sca1+ CPCs, it could be speculated that this 
therapy could also offer the patient-specific benefits, since after patient’s CPCs 
isolation it would be possible to expand and transplant them into the injured 
myocardium. Indeed, in Figure 1.1  there is a schematic representation of how 
isolated cardiovascular progenitors (which can comprehend adult CPC’s) could 
be used (1) for direct transplantation or (2) cultured and differentiated as a 
source of cardiomyocytes for further transplantation or patient-specific disease 
modeling (Davis and Stewart, 2011; Garbern et al., 2013). 
In an early 2013 study published in Nature by Senyo and colleagues, it was 
shown how pre-existing cardiomyocytes could be the major source of new 
cardiomyocytes found in adult mammals’ hearts, contributing to myocardial 
turnover. Interestingly, these new cardiomyocytes derived from already existing 
cardiomyocytes showed to be more abundant in areas adjacent to myocardium 
injuries, correlating them to a strong contribution for myocardium regeneration 
(Senyo et al., 2013). As so, exploring this mechanism – transplanting already 
differentiated cells into the injured areas (e.g. cardiomyocytes) – can be 
identified as another approach for cardiac cell-based therapies. Such strategy 
seems a safer alternative than all of the ones considered so far, as with 
engraftment cells would substitute the exact same cell types lost during an 
ischemic event, and their capacity to cause tumors in the host organism is 
rather lower then pluripotent cells. In fact, earlier studies on this approach in 
rats has proven the technique to be feasible, for the transplanted 
cardiomyocytes engrafted the host tissue, proliferated and formed cardiac 
tissue. In addition, transplanted cells were connected to each other by 
intercalated disks and the newly formed tissue was also more vascularized then 
the remaining scarred tissue, however their overall arrangement was 
disorganized when compared to the host cardiac tissue (Li et al., 1996; 
Sakakibara et al., 2002). Even though this proves it is possible to transplant 
cardiomyocytes into ischemic injuries, the authors address some concerns with 
this technique, such as the used cardiomyocytes being from newborn mice and 
have being rejected after several weeks post-transplantation. Interestingly, in a 
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different study it was indicated that cardiomyocyte transplantation only inhibited 
the progress of cardiac remodeling in chronic myocardial infarction and did not 
improve cardiac function significantly (Sakakibara et al., 2002). Nevertheless, to 
test the viability and efficiency of such approach in humans there would be 
starting limitations needing to be addressed such as developing protocols that 
allow a scalable, yet ethical, production of cardiac cells for further 
transplantation.  
One attractive and safe way to achieve this goal could be the use of secreted 
factors that promote the cardiogenic potential of pluripotent stem cell (both 
ESCs and iPSCs) or CPCs (Hansson and Lendahl, 2013), but examples in the 
literature of such factors are still limited (Czyz and Wobus, 2001; Hashimoto 
and Yuasa, 2013; Khezri et al., 2007; Sato et al., 2006; Takahashi et al., 2003; 
Zeng et al., 2013). However, combining factors such as hypoxia and 
bioreactor’s hydrodynamics has shown to be an interesting approach to 
efficiently maximize the production of cardiomyocytes from iPSCs (Correia et 
al., 2014). Nonetheless, there is still room for significant improvements in such 
protocols – on how to alternatively modulate pluripotent or multipotent cell 
lineages to achive their full cardiogenic potential – as another challenging 
limitation is related to the non-maturation state these engineered 
cardiomyocytes present. 
2.3. Cardiac patches and scaffolds in cardiac repair 
Myocardial infarction leads to ventricular weakening by replacement of the 
cardiac muscle fibers by non-functional fibrotic scar tissue, leading to ventricular 
dilation and wall thinning. To avoid this, actual research is also being developed 
to design cardiac patches that help to improve these defects upon injury. 
Cardiac patches are three-dimensional scaffolds engineered from natural or 
synthetic polymers which aim to be engrafted on the site of the injury to help 
avoiding the progressive impairment of surrounding healthy tissue, and on the 
other hand also by improving the restoration of the lost functions. By mimicking 
the extracellular matrix (ECM), cardiac patches can stimulate to a limited extent 
biological processes such as cell adhesion, proliferation and migration, which 
intend to drive tissue regeneration. In fact, Holubec et al. reviews how the use 
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of different porcine small intestinal submucosa ECM-derived products in clinical 
cardiac surgery offers the potential for cellular repopulation and growth in 
different damaged cardiac tissues (Holubec et al., 2014). However, some 
approaches of engineering such patches can include the encapsulation of living 
cells into the polymer mesh, resembling a sheet of living tissue with closer 
similarity to native myocardial tissue.  
To have a clinically relevant effect on damaged hearts, such cardiac patches 
should have around 1 cm of thickness, be able to generate between 20-
50nN/mm2 and also be able to propagate electrical impulses around 25 cm/s 
(as clearly reviewed and described in Radisic and Christman, 2013). Even 
though so far the small size of viable cardiac patches for transplantation has 
been a limitation, Martínez-Ramos and colleagues have recently developed a 
scalable way to produce injury-size patches which can be grafted into the site of 
the injured myocardium. While producing scaffolds with similar myocardial 
physical properties such as elasticity, flexibility and stiffness had been a 
challenge, this latter group was able to combine a poly (ethyl acrylate) (PEA) 
scaffold, with self-assembly peptide (SAP) hydrogel RAD16-I and ASCs 
biohybrid patch that overcomes such limitations (Martínez-Ramos et al., 2014). 
This clearly shows that synergisms can be created by combining different 
regenerative strategies. Indeed, in the 6-months follow-up study to their animal 
models, enhanced systolic and diastolic parameters and also the reduction of 
the infarct area were identified. Along with the regeneration of the lost 
myocardium tissue, proper local vascularization of the injured tissue, or even of 
the engrafted patch, is a requirement for a successful strategy. To meet that 
need, Ichiara’s team have recently developed a biodegradable surgical patch 
for high pressure systems that enables the incorporation of endothelial cells 
(ECs) and smooth muscle cells (SMCs) in the scaffold, therefore opening the 
way to create vascular grafts (Ichiara et al., 2015). 
2.4. Current challenges and future directions on cardiac tissue 
repair 
As some of the cell-based therapies have shown a significant but yet modest 
improvement of the cardiac function, primarily related to paracrine effects of the 
transplanted cells, cell-homing can play an important role in raising the 
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efficiency of such approaches. Taghavi and George review many cell-adhesion 
markers, growth-factors, chemokines, endothelial nitric oxide synthase and 
hormones responsible to enhance the homing of transplanted cells to the 
injured myocardium (Taghavi and George, 2013). Despite such promising 
alternatives to enhance the efficacy of current cell-based therapies, there 
seems to be strong suggestions that combining cardiac patches with cell-based 
therapies can already increase the time window of transplanted cells’ homing 
and residency on the local of interest. So whether is by increasing the time of 
exposure of the damaged tissue to the paracrine effects of metabolites 
produced by the engrafted cells, or whether is by actually easing the homing of 
more differentiated cell populations (eg. cardiomyocytes and endothelial cells) 
into the injury site, the way these strategies are evolving offer a very promising 
fashion in helping the regeneration of the heart. 
3. Mammalian Heart development: from defined progenitor 
populations to a 4 chambered organ 
A better and more detailed understanding of the mechanisms involved in 
mammalian embryonic cardiogenesis would be beneficial for the development 
of novel cardiac regenerative therapeutic approaches. 
With the growth and development of the embryos, which limits the access to 
oxygen and nutrients to all the cells, novel embryonic cardiovascular structures 
are formed to ensure a sufficient supply of nutrients and oxygen to all the cells, 
and to remove efficiently the cellular waste products. Consequently, around the 
3rd week in human embryos and embryonic day (E) 8.5 in mouse embryos,  
populations of cardiogenic cells start forming the heart to ensure these 
functions, being the heart the 1st organ to be formed during development (Brade 
et al., 2013; Carlson, 2014). Due to the conserved similarity in mammalian heart 
development, mouse cardiogenesis is considered to be a good model for 
unraveling mechanisms of human heart development. Interestingly, studies in 
mouse models have determined that specific regions of the embryo are pre-
assigned to give rise to specific cardiac structures.  
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During gastrulation, both in mouse and human embryos, precardiac 
mesodermal cells expressing Brachyury (T) and Mesp1 leave the primitive 
streak associated with endodermal cells composing the splanchnic mesoderm 
(Figure 1.2A). Later, these cells migrate anteriorly and adopt a U-shaped 
disposition – the cardiogenic mesoderm, also called the cardiac crescent (Brade 
et al., 2013). The endodermal cells that migrate most anteriorly from the 
 
Figure 1.2 – Cardiac mesoderm formation during gastrulation is conserved in 
human and mice embryos. A) In human, during gastrulation T+ mesodermal cells, 
Mesp1+ precardiac mesodermal cells and endodermal cells leave the primitive streak 
migrating anteriorly and formatting the mesoderm and the endoderm; B) Bmps, 
released from the newly formed endoderm, signal the formation of a cardiogenic 
lineage from the mesoderm (red cells), but their influence is limited to the lateral 
mesoderm because of the release of chordin and noggin from the notochord and 
Wnt1/3a from the forming neuroectoderm. NF, Neural fold; PN, primitive node. 
Adapted from Schoenwolf, 2015. 
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primitive streak will form the definitive endoderm which is crucial for cardiac 
mesodermal cells specification. This process is conserved in mice and human 
embryos (Lewis and Tam, 2006). During its formation, this structure secretes 
cardiogenic inductive signals such as bone morphogenic proteins (Bmps), 
fibroblast growth factor (Fgf), activin, insulin-like growth factor 2 (Igf2) and sonic 
hedgehog (Shh). These factors contribute to the commitment of mesodermal 
cells to cardiac fates, and also promote their proliferation and survival (Lewis 
and Tam, 2006; Schoenwolf, 2015). 
3.1. Endoderm genetic networks defines cardiogenic 
mesoderm 
However all the mesoderm in exposed to these signals, only the cranial part of 
the lateral mesoderm commits to cardiac fates. In one hand, the lateral 
specification is related to the inhibitory effects that secreted factors by both the 
notochord and the neural tube exert on the Bmp signaling (Figure 1.2 B).  
Chorddin and Noggin are secreted by the notochord, and act by sequestering 
Bmps, keeping them from binding to their receptors. Wnt1 and Wnt3a are 
secreted by the neural tube and are antagonizers of the Bmp signaling (Figure 
1.2 B; Schoenwolf, 2015). On the other hand, the cranial specification results 
from the secretion of dickkopf proteins by the cranial definitive endoderm, and 
from the presence of frizzle-like proteins (sFrps) on those same cells. While 
sFrps will sequester the Wnt molecules secreted in the cranial mesoderm, 
dickkopfs molecules will act by binding both to the Wnts and its co-receptors, 
abrogating their cardiogenic inhibitory signal (Schoenwolf, 2015).  Bmp2 
signaling will hence act restrictively as an early stimulus to the expression of 
early cardiogenic transcription factors within the lateral mesoderm, such as 
Nkx2.5 and Gata4, and its role is also conserved in other vertebrates (Carlson, 
2014, Andrée et al., 1998; Schultheiss et al., 1997). For this reason these early 
mesodermal cardiogenic fields are located bilaterally and later merge to form 
the cardiac crescent. From this structure two distinct pools of cells can be 
identified through the expression of unique markers which give rise to specific 
cardiac structures: the first heart field (FHF) and second heart field (SHF) 
populations (Kelly et al., 2001; Abu-Issa et al., 2004). 
  Chapter I - General Introduction  
13 
 
3.2. Two defined cardiac progenitor populations 
The FHF cardiac progenitors are known to express Nkx2.5 (red cell population 
in Figure 1.3 and Figure 1.4) soon after the onset of gastrulation under the 
influence of Bmps secreted by the adjacent endoderm, and are derived from 
splanchnic mesoderm, which gives rise to the heart tube and subsequently will 
contribute to the left ventricle and atria (Dehaan 1963, Zaffran et al., 2004; 
Meilhac et al., 2014; Carlson, 2014). The SHF progenitors are characterized by 
the expression of Isl1 (green cell population in Figure 1.3 and Figure 1.4),, 
which together with the Gata transcription factors will drive the expression of a 
specific SHF enhancer of Mef2c in pharyngeal mesoderm, the embryonic region 
 
Figure 1.4 – Genetic origin of cardiac components. Genetic tracing with a 
Mesp1-Cre and Rosa26 conditional reporter shows that almost all cardiac cells in the 
heart are labeled, so that Mesp1 marks all cardiac progenitors. 
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Figure 1.3 – Contribution of the heart fields to the mature tissues of the mature 
heart and head. First heart field (red; FHF) and second heart field (SHF; green) and 
anterior (pale green/yellow) or posterior (dark green) subdomains of the SHF are shown 
at different stages of heart and head development. Regions of the heart with a dual 
origin are shown with colored dots. ao, aorta; LA, left atrium; LSCV, left superior caval 
vein; LV, left ventricle; OFT, outflow tract; pt, pulmonary trunk; PV, pulmonary vein; RA, 
right atrium; RSCV, right superior caval vein; RV, right ventricle. Adapted from Meilhac 
et al., 2014 
 
where this lineage is derived from. Nkx2.5 enhancer in the SHF is then 
activated by these two transcription factors, leading to its expression in this 
second pool of embryonic cardiac progenitor cells (Meilhac et al., 2014; Kelly 
and Evans, 2010). SHF progenitors hence lie medial and slightly caudal to the 
FHF within the lateral plate mesoderm (Figure 1.3; Schoenwolf, 2015). At E8.0 
in mouse and 3rd week in humans, the primordial heart tube is composed mainly 
by FHF progenitors when the cardiac crescent fuses at midline, after which it 
starts beating and undergoes rightward looping (Zaffran et al., 2004). 
Proliferating cells from the SHF start to migrate to the newly-formed heart tube 
contributing to its elongation and growth at both arterial and venous poles 
(Figure 1.3). SHF progenitors will give rise to the outflow tract, right ventricle 
and atria of the developing heart (Buckingham et al. 2005; Kelly et al. 2001). At 
day 32 in human gestation and E10.5 in mice, the heart presents a well-defined 
4 chamber structure, which resembles the form it will have as a mature heart 
(Brade et al., 2013). 
While most of the FHF- and SHF- derived cells are going to mature into 
cardiomyocytes and compose the myocardium, other cell types found in the 
heart, i.e. smooth muscle cells (SMCs) and cardiac fibroblasts (CF), will arise 
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from the epicardium. The proepicardial organ is marked by the expression of 
Tbx18 and Wilm’s tumor protein-1 (Wt1), and is the embryonic structure that 
gives rise to the epicardium (Figure 1.4). This structure derives from a 
specialized group of cells within the splanchnic mesoderm during E9.5 in the 
caudal dorsal mesocardium/septum transversum junction (Meilhac et al., 2014). 
As the heart looping starts, these cells will start migrating in order to cover all 
the surface of the myocardium and form the epicardium, and then will undergo 
epithelial-to-mesenchymal transition (EMT) to enter the myocardium and give 
rise to CFs and SMCs of the coronary vasculature (Meilhac et al., 2014; 
Carlson, 2014; Schoenwolf, 2015).  
3.3. ECM in cardiogenesis: collagens and fibronectin 
The ECM provides structural support for the formation and maintenance of 3 
dimensional organs and tissues within an organism. However, the ECM is also 
a communication net of molecules that allow cells to sense and interpret the 
environment around them. As a response to those stimuli cells can undergo 
many cellular processes such as adhesion, migration, proliferation, apoptosis, 
transformation, and even secrete to that same net additional factors, giving 
back a response to the surrounding environment. How cells interact with each 
other and with the surrounding ECM is hence important for the continued 
understanding of cardiogenesis and cardiac defects (Bowers and Baudino, 
2010). 
One of the earliest contributions of the ECM to the developing embryonic heart 
happens before the migration of the mesenchymal cardiac cells to an acellular 
compartment called the cardiac jelly, located between the myocardium and 
endocardium of the primitive heart tube. In the mammalian heart the ECM is 
mostly composed by collagens (Col) of types I, III, IV, VI, fibronectin (FN), 
laminin (LN) and elastin (Schenke-Layland et al., 2011; Burggren and Keller, 
1997). Even though it is not possible yet to understand the role of each one of 
these single components of cardiac ECM, relevant information is already known 
on the roles of the FN and Col I, Col IV and LN. In the case of the FN it is 
known that its loss-of-function in mice leads to severe cardiac malformations 
(George et al., 1993). More recently, is was described that proliferating niches 
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of Isl1+/Flk1+ cardiac progenitor cells within the right ventricular free wall, the 
atria and outflow tract of both mouse and human developing hearts, were 
characterized by a rich Col IV and LN ECM. Indeed, data from the same report 
strongly suggested that such ECM composition was important to maintain 
cardiac progenitors in an undifferentiated state, prior to their migration to 
populate other parts of the heart. Interestingly, while cardiac progenitors 
migrated from the niche, the surrounding ECM rich in Col I and FN promoted 
their differentiation towards cardiomyocytes and vascular cells as Isl1 
expression was downregulated and cells started to express Troponin C (TnC; 
Schenke-Layland et al., 2011). 
It is getting clear now the determining role of the ECM composition in the 
developing heart. Now the aim is to try to understand what particular cellular 
processes do these components regulate and promote in the heart, in order to 
also exploit such mechanisms in therapeutics (Bowers and Baudino, 2010). In 
the next section, with the explanation of why are pluripotent stem cells (PSCs) a 
good model for embryonic cardiogenesis, there will also be addressed some 
findings that have been made to better understand the role of Col I, Col IV and 
FN in controlling cellular processes using in vitro models. 
4. Mouse and human pluripotent stem cell differentiation in vitro 
recapitulate cardiac differentiation 
As mentioned earlier, ESCs offer a very promising potential as a source of cells 
for heart regeneration. In fact, ESCs and iPSCs by being PSCs, when 
manipulated and differentiated in vitro allow the possibility to recapitulate some 
of the crucial steps for cardiac specification. Indeed, it is possible to derive cells 
expressing specific genetic markers of both early- and late- cardiogenesis by 
differentiating PSCs. However, whether is in vivo or in vitro, the specification of 
the cardiovascular lineages involves a transition through a sequence of 
increasingly restricted progenitor cells, proceeding from a pluripotent state to 
mesoderm and then to cells committed to cardiovascular fates (Figure 1.5; 
Laflamme and Murry 2011). Culturing and differentiating mouse PSCs as cell 
aggregates, called embryoid bodies (EBs), has become a routine in many 
laboratories, since it was proved back in 1985 that spontaneous in vitro 
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differentiation of ESCs could give rise to cells from the 3 embryonic germ-layers 
(Doetschman et al. 1985). At the same time the differentiation protocol is 
triggered on PSCs after removal of Leukemia inhibitory factor (LIF) from the 
culture medium the cells are cultured in hanging drops (Figure 1.6Figure 1.). This 
technique, which requires the preparation of a cell suspension with a precise 
cell density, allows the aggregation of the cells with the stimulus of the gravity 
since these cell suspension drops are cultured in inverted bacterial dishes. After 
they aggregate, they become EBs, resembling the inner cell mass of early 
embryos. Simultaneously with this physical change, cells also lose the 
expression of the pluripotency genes Nanog, Oct4 and Sox2, and start 
expressing germ-layer specific genes. As the EBs grow in size, they form an 
outer shell-like layer composed of cells and an enriched collagen IV and laminin 
 
Figure 1.5 – Growth factors and key transcription factors that regulate fate 
choices during early embryonic cardiogenesis and ESCs differentiation. Growth 
factors that regulate fate choices are listed at branch points (green), and key 
transcription factors and surface markers for each cell state are listed under the cell 
types (blue). The growth factors are useful for directing the differentiation of ESCs, 
whereas the markers are useful for purifying cells at defined developmental states. 
BMPs, bone morphogenetic proteins; CNTN2, contactin-2; CX, connexin; FOXA2, 
forkhead box protein A2; HCN4, potassium/sodium hyperpolarization-activated cyclic 
nucleotide-gated channel 4; MESP, mesoderm posterior protein; MLC2a/v, myosin 
light chain 2a and/or 2v; MYH, myosin heavy chain; NPPA, natriuretic peptide 
precursor A; NRG1, neuregulin 1; PDGF, platelet-derived growth factor; PDGFR, 
PDGF receptor; SCN5A, sodium channel protein type 5 subunit α; SOX, SRY-related 
high-mobility-group box; TBX, T-box transcription factor; VEGF, vascular endothelial 
growth factor; VEGFR-2, VEGF receptor-2. 
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extracellular matrix (ECM), that can act similar to the endoderm in the embryos 
by secreting mesoderm inducing morphogens (Li et al., 2001). In fact around 
day 3, such external layer of cells starts expressing the endoderm-specific 
genes α-fetoprotein (αfp) and galactosamine epitopes until all the outer shell-
like layer is formed by day 4 (Weitzer, 2006). Also during day 3, T which is 
responsible for inducing mesoderm formation in the embryo starts to be 
expressed, and is therefore an early mesodermal indicator in differentiating 
PSCs. After mesoderm specification it is possible to identify transient Mesp-1 
and Mesp-2 expression around day 4 in EBs, which are markers of early 
cardiac commitment. Similarly, in the embryo its expression can be found 
transiently on the primitive streak prior to migration to the cranial region of the 
embryo where they become cardiac progenitors (Weitzer 2006; Schoenwolf, 
2015). When occurs cardiac mesoderm specification, different early cardiac 
markers start to be expressed, such as Nkx2.5, Isl1, Gata4 and Tbx18 
(reviewed in Meilhac et al., 2014) and such markers can be found to be 
expressed in differentiating PSCs. After plating the EBs on gelatin-coated 
culture dishes at day 6, they form cellular structures that within a couple of days 
start beating and are hence called beating foci. These structures are indicative 
of cardiac differentiation, and so it is that mature-specific cardiac markers like 
cardiac Troponin T (TnT) and myosin chains encoding genes (light and heavy 
chains) start to be expressed. Nonetheless, contrasting with the organized way 
gastrulation occurs in developing embryos, the way cells commit to cardiac 
fates in differentiating EBs is rather stochastic, and hence referred to 
spontaneous differentiation (Weitzer 2006). 
  
Figure 1.6 – Schematic representation of the hanging droplet method used to 
differentiate ESCs. Undifferentiated ESCs are maintained in culture for 2 passages 
prior to differentiation with medium supplemented with LIF. A cell suspension is 
prepared and cells are put to grow in droplets on an inverted bacterial dish for 2 days, 
and EBs grow in suspension four additional days. At day 6 of differentiation the formed 
EBs are plated in to gelatin-coated 6-well plates. 
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Similar to what was described in vivo ColI, ColIV and FN have important roles in 
promoting the differentiation of PSCs towards cardiac lineages, meaning that 
the ECM found in differentiating EBs plays also an important role. In fact at day 
4 of differentiation, as the EBs commit to early cardiac lineages expressing 
Mesp1, Isl1 and Flk1, it is shown that the ECM surrounding these cells is rich in 
ColIV (Schenke-Layland et al., 2011). In addition, culturing undifferentiated 
ESCs in ColIV substrates was shown to effectively enhance the fold number of 
Flk1+ cells, while posterior culturing Flk1+ cells in a FN substrate led to 
expression of αMhc, an early indicator of mature cardiomyocytes. In the one 
hand, this strongly supports that ColIV is indeed required for the earlier stages 
of cardiac commitment, proliferation and maintenance of cardiac progenitors in 
an undifferentiated state. On the other hand, these data supports that once the 
cells are committed to a cardiac fate, they get sensitive to FN and respond to 
that stimulus by differentiating into cardiomyocytes (Schenke-Layland et al., 
2011). Additionally, inhibiting the synthesis of ColI or blocking its interaction with 
β1 integrin receptors in differentiating PSCs leads to failure on cardiac lineages 
commitment and specification, showing it also has an important role on cardiac 
differentiation and hence is an important cardiac ECM component (Zeng et al., 
2013). Of interest, our molecule of study is also a secreted protein and a 
prospective cardiac ECM component, and was already implied in cellular 
processes such as cell migration and proliferation in the heart, as it will be 
explained in detail in section 6. However, its role and function in cardiac 
differentiation is not well known. 
As described before, there are mainly two pools of progenitor cells in the 
embryo that give rise to the heart - FHF and SHF. These progenitors have only 
recently been described in mouse ESCs. To do so, these authors generated a 
transgenic mouse with the red fluorescent protein dsRed under the control of an 
Isl1-dependent enhancer of the Mef2c gene whose expression is restricted to 
the SHF. This mouse line was then bred with another transgenic mouse line 
containing the enhanced green fluorescent protein (eGFP) controlled by the 
cardiac-specific Nkx2.5 enhancer (Domian et al., 2009). With the expression of 
these fluorescent markers it was possible to isolate from developing hearts, cell 
populations expressing one, both or none of these reporters, corresponding to 
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populations of the FHF, SHF and non-cardiac cells as a control. After, 
blastocysts from these transgenic mice were isolated in order to establish a 
double transgenic ESC line model, which aimed to become a powerful tool to 
study the divergent origin of the different cardiac progenitor populations 
(Domian et al., 2009). By being a good model for embryonic cardiogenesis we 
chose to work with this double transgenic ESC line as they differentiate into 
some of the different cardiac populations existing in the developing heart. 
5. Identification of genes (splice variants) involved in cardiogenesis: 
DNA microarrays Vs RNA sequencing 
Growth factors or genes that regulate fate choices of differentiating PSCs can in 
fact offer a powerful tool to boost the production of a desired cell type (known 
examples in Figure 1.5). Since there are a lot of complex genetic networks 
interacting during cardiogenesis, the need to identify the factors that could 
ultimately be manipulated to increase in vivo or in vitro the number of 
cardiomyocytes or cardiac progenitors for heart regeneration applications, is a 
field worth exploring. Performing DNA microarrays has been the predominant 
technique used in the past decade to measure gene expression levels, to 
identify transcription factors’ binding sites and to genotype single-nucleotide-
polymorphisms (SNP), allowing biologists to explore vast amounts of complex 
digital data. According to this, in our lab was carried out a differential screening 
using Affymetrix GeneChip system technologies to enable us to identify and 
study genes expressed and involved in the correct development and 
differentiation of the vertebrate cardiac progenitor cell lineages. Indeed, this 
screening led to the identification of more than 700 transcripts differentially 
expressed in the heart forming regions (HFR), which after bioinformatical 
analysis and in vivo validation, this number was cut down to a few more than 
150. Collagen and calcium-binding EGF domain-containing protein 1 (Ccbe1), 
our gene of study and interest, was identified among the new genes potentially 
expressed in the heart precursor cells (Bento et al., 2011). However DNA 
microarrays have been incredibly useful in a wide variety of applications, they 
can be particularly problematic for gene families and for genes with multiple 
splice variants (Bumgarner, 2013).  
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During pre-mRNA maturation to mRNA, alternative splice sites in one gene 
transcript may give rise to different protein isoforms that differ in their peptide 
sequence, having consequently different biological and chemical activities. And 
in fact many genes are known to have several splicing patterns or even 
thousands (Black, 2003). Now, as the costs of sequencing became cheaper, 
sequencing is a feasible unbiased approach to measure which nucleic acids are 
present in a given solution. In addition, it is also independent of our prior 
knowledge of which nucleic acids may be present and so it can detect closely 
related gene sequences, novel splice forms or RNA editing that may be missed 
due to cross hybridization on DNA microarrays (Bumgarner, 2013). RNA 
sequencing (or simply RNA-seq) is a whole genome transcriptome analysis that 
allows us to quantify the gene expression in a genome-wide fashion and in a 
given moment in time. Taking advantage of such technique presents an 
additional way to identify some of the yet unknown genes or growth factors that 
regulate cardiogenesis. Nonetheless, at the same time will allow us to identify if 
some of the already well known cardiac genetic players have different isoforms 
depending on the nature of the cardiac progenitor population, or if within the 
same population these change with time. 
6. Ccbe1  
6.1. Protein Structure and Identity 
Ccbe1 encodes a 408 amino acid secreted protein with a calcium-binding EGF-
like domain, which has 89% identity with the 406 amino acid human ortholog 
CCBE1. Even though it is still not possible to determine the correct structure of 
this protein, it possible to highlight some of the features it has by analyzing its 
primary amino acid sequence. By aligning mouse and human Ccbe1 sequences 
(Figure 1.7) and blasting against protein databases, Ccbe1 is shown to have 1 
peptide signaling for secretion, 2 collagen domains, 1 calcium binding EGF-like 
domain, 1 predicted EGF-like domain and 2 glycosylation sites that could be 
responsible for further protein modifications.  
6.2. Lymphangiogenesis and Hennekan Syndrome 
During E9.5 in mouse development Ccbe1 is shown to be expressed in tissues 
surrounding the anterior cardinal vein where Prox1+ lymphatic endothelial cells 
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(LECs) are also present (Figure 1.9; Facucho-Oliveira et al., 2011; Bos et al., 
2011). At this stage of development, Ccbe1 appears to be mostly involved in the 
development of the lymphatic system. Indeed, Ccbe1 loss-of-function in mice 
leads to prenatal death due to the loss of definitive lymphatic structures 
resulting in generalized lymphedema, which is a consequence of dramatic 
reduction of the number of Prox1+ and Lyve1+ LECs (Bos et al., 2011). 
Moreover, from E10.5 onwards Ccbe1 is indeed required for the formation of 
LECs themselves, but additionally also for their consequent budding and 
migration from the anterior cardinal veins to give rise to the lymphatic 
vasculature, where in its absence LECs form dilated sprouts or bag‐like sacs, 
which always remain connected with the cardinal vein (Bos et al., 2011; 
Hagerling et al., 2013). Interestingly, after being showed that administering 
CCBE1 together with VEGF-C could increase the yield in lymphangiogenesis in 
 
Figure 1.7 – Mouse and Human Ccbe1 protein alignment. Protein domain 
sequences, predicted domain sequences, ion binding and glycosylation sites and 
disulfide bonding cysteines are highlighted in different color code. Signalling peptide for 
secretion (pink); Predicted EGF-like domain (blue); Calcium-binding EGF-like domain 
(yellow); Calcium (Ca2+) binding sites (red arrows); Cysteine residues forming dissulfide 
bonds (green; cysteines bonding position: 138↔150; 146↔159; 161↔174); 
Glycosylation sites (orange); Triple helix collagen domains (brown). The alignment was 
performed using CLUSTAL O (1.2.1) multiple sequence alignment. 
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corneas, suggesting a role in VEGF-C modulation, it was shown that CCBE1 
functions during lymphangiogenesis by helping in the maturation of the pro-
VEGF-C through the interaction with the metalloprotease ADAMTS3 (Figure 
1.8; Bos et al., 2011; Jeltsch et al., 2014). Likewise, ccbe1 in zebrafish has also 
been associated with the development of the lymphatic vasculature and venous 
sprouting using the same mechanism, even though due to the lack of early 
lymphatic markers it is not clear whether ccbe1 is also needed for lymphatic 
precursor cells fate commitment (Hogan et al., 2009; Le Guen et al., 2013; Astin 
et al., 2014). On the other hand overexpression of mature vegf-c in zebrafish is 
capable of rescuing the deficits found in lymphangiogenesis in the absence of 
ccbe1, shedding light on the conserved role ccbe1 has in modulating the vegf-c 
signaling (Le Guen et al., 2013). While it was firstly suggested that the CCBE1 
EGF-like domain is essential for the maturation of VEGF-C (Bos et al., 2011; 
Jeltsch et al., 2014), more recently in an attempt to perform additional functional 
domain analysis of CCBE1, it was possible to show that its collagen domains 
 
Figure 1.8 - Schematic view of the function of CCBE1 in lymphangiogenesis.  
Pro–VEGF-C binding to VEGFR-3 is assisted by the N-terminal domain of collagen- 
and calcium-binding epidermal growth factor domains 1 (CCBE1). Pro–VEGF-C is then 
proteolytically processed in situ by the metalloprotease ADAMTS3, and the mature 
VEGF-C activates VEGFR-3. Note that the transparently illustrated elements are 
hypothetical: VEGFR-3 could be either monomeric or dimeric during the initial binding 
of VEGF-C, and it is not known whether the removal of the C-terminal domain of 
CCBE1 is required for the CCBE1 function. Adapted from Jeltsch et al., 2014. 
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are also essential. Indeed, the collagen domains of CCBE1 were found to 
function in activating the VEGF-C both in vivo and in vitro models, rather than 
binding to the ECM, like many collagen proteins (Roukens et al., 2015). 
However, as an ECM protein itself there are also proposed interactions of 
CCBE1 with other ECM components such as vitronectin, in order to localize it in 
vivo in tissues were it mediates activation of growth factors such as VEGF-C, as 
a cue for cellular processes like migration in the case of LECs in 
lymphangiogensis (Jeltsch et al., 2014). Indeed, a truncated fraction comprising 
the EGF-like domain of CCBE1 was found to bind to ECM proteins vitronectin, 
ColI and ColV (Bos et al., 2011).  
In humans, mutations in CCBE1 have been associated with Hennekam’s 
syndrome (HS), a rare autossomal recessive syndrome characterized by 
defective lymphatic development. Of the several mutations identified so far, the 
more commons are found to be in the N-terminal portion of the protein, which 
corresponds to the EGF-like domain. However some others also have the 
mutation on the C-terminal portion, corresponding to the collagen domains 
(Alders et al., 2009). The patients present limb lymphendema, 
lymphangiectasias, mental retardation, and also unusual facial characteristics 
(Alders et al., 2009; Connel et al., 2010; Frosk et al., 2015). It is likely that all 
these patients are hypomorphs, as even though mutation occurs, the protein 
might still preserve some minimal function, since the total absence of Ccbe1 in 
mice is rather lethal (Bos et al., 2011). So altogether, it is clear the indisputable 
key role of CCBE1 in lymphagiogenesis, and the way CCBE1 acts is embryonic 
process is likely by providing positional information for VEGF-C signaling, which 
orchestrates the migration of LECs (Roukens et al., 2015). 
6.3. Carcinogenesis, proliferation and migration 
In a thorough expression analysis of the 18q21-qter chromosomal region, where 
gene losses are frequent in breast cancer, primary breast cancer cell lines were 
found to have strong downregulation on the expression of CCBE1 (Yamamoto 
and Yamamoto, 2007). Down-regulation of CCBE1 was additionally identified in 
ovarian cancer cell lines and primary carcinomas (Barton et al., 2010). Because 
the domains of CCBE1 are found in some of the extracellular matrix proteins, 
the loss of CCBE1 protein expression could possibly result in changes in 
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cellular characteristics, such as adhesion and motility. Indeed, siRNA-mediated 
knockdown of CCBE1 in ovarian cancer cell lines enhanced cell migration; on 
the other hand, re-expressing CCBE1 in the same cell lines was sufficient to 
reduce cell migration and survival. Hence, in carcinogenesis the way CCBE1 
loss of expression may act is by enhancing migration and cell survival 
(Yamamoto and Yamamoto, 2007; Barton et al., 2010). Such findings are 
interesting, as they suggest CCBE1 to be involved in metastization by 
enhancing cell migration. However, the mechanism through which CCBE1 
might be involved in migration of carcinogenic cells is likely different from the 
mechanism involved in the impaired migration of LECs in lymphangiogenesis. 
While in lymphangiogenesis the lack of Ccbe1 is rather involved indirectly in 
migration, as it impedes the maturation of the Vegf-c as the leading migration 
cue for the LECs, on carcinogenesis its involvement seems related to a more 
direct mechanism. Cell migration experiments in Ccbe1 knockout (Ccbe1-/-) 
mouse embryonic fibroblasts (MEFs) were carried out by our laboratory to 
better understand its role in migration. Interestingly, it was shown that 
comparing to wild-type (Wt) MEFs, Ccbe1-/- MEFs were found to have 
enhanced migration capacity, similar to what happens in carcinogenesis 
(Perestrelo et al., in preparation). This recently new data is in agreement with 
another previous report from our lab where modulating Ccbe1 expression 
during chick heart development leads to abnormal cell migration during primitive 
heart tube fusion (described in section 1.6.4; Furtado et al., 2014). Since these 
cardiovascular progenitors rely on ECM cues for migration, and it was also 
shown that CCBE1 interacts with ECM proteins (Bos et al., 2011), it was 
hypothesized a mechanism where CCBE1 interacts with the ECM providing or 
inhibiting the migratory stimuli. In fact, Ccbe1-/- MEFs have higher expression of 
proteolytic enzymes, which can be activated through ECM components and be 
responsible for a higher ECM degradation and hence a higher migration 
capacity. Therefore our data fits a model where in contexts where the ECM 
provides the migratory stimuli, such as what happens in carcinogenesis, CCBE1 
seems to act as an antagonist (Unpublished data). However, further studies are 
still required to identify what molecules interact with CCBE1 or are involved in 
such migration process. 
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While in one hand cell migration is enhanced in Ccbe1-/- MEFs when compared 
to Wt MEFs, survival assays show Ccbe1-/- MEFs to have a decreased cell 
proliferation (Unpublished data). In agreement with this data it had been 
described previously that the loss of Ccbe1 could also lead to a reduced 
number of Lyve1+/Prox1+ lymphatic progenitor cells (Bos et al., 2011). So 
altogether it is likely that apart from its role in cell migration, Ccbe1 is also 
somehow involved in cell proliferation. 
6.4. Cardiogenesis 
Prior to the lymphatic system development and to its expression on 
lymphangiogenic regions in the embryo, Ccbe1 has also expression in 
cardiogenic embryonic regions. At first, expression analysis carried out by our 
lab showed that Ccbe1 is expressed in the early cardiac progenitors of the two 
bilateral cardiogenic fields at E7.0, and in the cardiogenic mesoderm from E7.5  
- E8.0 (Figure 1.9 A-D). At E8.25 (Figure 1.9 E-F) Ccbe1 showed persistently 
expression in the pericardium and transiently expression in the myocardium of 
the primitive heart tube. Later its expression is detected in the proepicardium 
(Figure 1.9 G-H). Within these regions its expression is detected in all the FHF, 
SHF and proepicardium cells during early mouse heart organogenesis from 7.0 
– 8.75 (Facucho-Oliveira et al., 2011) raising the possibility that Ccbe1 may play 
a role in cardiac development. Interestingly, prior work has also shown that 
Ccbe1 is expressed in the pericardium at E11.0 and E12.5, even though at 
these stages its expression is more related with lymphangiogenesis as 
described in section 6.2 (Bos et al., 2011). In developing chick embryos Ccbe1 
was similarly found to be expressed in FHF and SHF populations during early 
heart development (Furtado et al., 2014).  
In HS patients, some of the patients also present congenital heart defects 
including hypertrophic cardiomyopathy and ventricular septal defects (Alders et 
al., 2009; Connell et al., 2010; Frosk et al., 2015). Such malformations have not 
been taken into account a probable involvement of Ccbe1 in heart development. 
Intriguingly, diseases that are related to defects in the development of the 
anterior pole of the heart may be accompanied by abnormalities of the skeletal 
muscles of the head, and are likely to arise from a defect in a common 
progenitor of the SHF and other derivatives (Figure 1.3; Schoenwolf, 2015). 
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Figure 1.9 – Ccbe1 expression pattern in cardiogenic regions during mouse 
embryogenesis. (A, B) A series of transverse sections extending from the head fold 
level towards to a more caudal positions showed that Ccbe1 is expressed in the 
cardiogenic plate (arrow in B’) and in the mesothelial precursors of the intra-embryonic 
coelomic cavity (arrow in B’’, B’’’); (C, D) Double WISH performed to detect Ccbe1 
mRNA (light blue) and Isl1 mRNA (dark blue) at E8.0 demonstrated that Ccbe1 is 
mainly expressed in FHF progenitors; although restricted overlap of Ccbe1 and Isl1 
staining confirms that Ccbe1 is also expressed in the SHF (C and blue arrow in D’’’). 
(E, F) At E8.25, Ccbe1 continues to delineate the pericardium cavity; lateral view, (E); 
anterior view (F). Ccbe1 mRNA was detected in the ventral mesothelium of the 
pericardium (F’), heart tube tissue adjacent to the ventral pericardium (arrow F’) and 
mesoderm lining the intra-embryonic coelomic cavity (F’’’). Double WISH reveals that 
Ccbe1 mRNA (light blue) continues to be partially colocalized with Isl1 (dark blue) at 
the level of the pharyngeal mesoderm (F’); (G, H) Lateral view of E9.5 embryo showed 
that Ccbe1 is expressed in the proepicardium, in the anterior cardinal veins (arrow) and 
in the somites (G, H). Transverse sections show that Ccbe1 expression in the heart is 
residual or non-existent (H’) but rather highly expressed in the proepicardium 
Chapter I - General Introduction 
28 
 
(arrowhead; H’’, H’’’), in the anterior cardinal vein (arrow; H’’, H’’’) and dermomyotome 
of the cervical somites (H’’, H’’’). Sagital sections further demonstrate that Ccbe1 
staining is located in the vicinity of the anterior cardinal vein (arrow) which during 
mouse development gives rise to important veins of the cardiovascular and lymphatic 
systems (I). Scale bars, 200 mm. Adapted from Facucho-Oliveira et al., 2011. 
 
Seemingly, the unusual facial characteristics of the HS patients can strongly fit 
this model, since Ccbe1 expression is found to be enriched in SHF progenitors 
of the studied animal models (Facucho-Oliveira et al., 2011; Furtado et 
al.,2014). in animal models, two recent studies, including one where an 
alternative Ccbe1 null mutant line with a mixedgenetic background that survives 
until birth was used, suggest that the heart of Ccbe1 mutant mice develops 
normally (Burger et al., 2015; Jakus et al., 2014). However, in embryonic 
cardiogenesis animal models, a recent report by our lab has shown the need for 
Ccbe1 in early chick heart development where both gain- and loss-of-function 
approaches led to incorrect fusion of the bilateral heart fields in order to form 
the primitive cardiac tube, which resulted in cardia bifida and in other cardiac 
malformations (Furtado et al., 2014). Additionally, it was also identified that 
Ccbe1 loss-of-function in mice is responsible for thinner/hypoplasical 
myocardial walls, a phenotype more evident on the compact layer of the 
developing right ventricle, which is related to the underdevelopment of the 
coronary vasculature (Pereira et al., in preparation). Additionally, co-culture of 
ESCs in Ccbe1-/- MEFs leads to decreased expression of cardiac marker genes, 
suggesting that secreted Ccbe1 by the fibroblasts is important for proper 
cardiac differentiation of ESCs (Unpublished data). Even though the exact 
molecular mechanisms by which this happens require further investigation, all of 
these data gathered so far strongly suggest that Ccbe1 plays an important role 
in heart organogenesis and in cardiac differentiation of ESCs.  
7. Objectives 
Despite the increasing evidence of a potential important role of Ccbe1 during 
cardiogenesis, its role in cardiac differentiation and development has not been 
further investigated. In this work I mainly aimed to perform an integrated study 
on the role of Ccbe1 in cardiac differentiation of ESCs in order to gather 
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knowledge about its involvement in the early cardiogenesis. To achieve this 
goal we used a double transgenic mouse ESC line which allows us to isolate 
different ESC-derived early cardiac progenitors and study Ccbe1 expression 
and its involvement in this stage of cardiogenesis. Also, by silencing the 
expression of Ccbe1 through short hairpin RNAs (shRNA) to generate stable 
knockdown ESC lines we were help to unveil on what biological pathways 
Ccbe1 plays an important role besides cardiogenesis. Additionally, gain-of-
function approaches were planned by producing and supplementing the ESCs 
differentiation medium with human recombinant CCBE1 to detect whether this 
protein can act as a guiding molecule in cardiac differentiation, with the ultimate 
goal of generating large amounts of cardiomyocytes to be used in regenerative 
applications. 
Furthermore, for the systematic study of alternative splicing, we aimed in firstly 
identify splicing events in mESCs and in cardiac progenitors on a genome-wide 
level using next-generation RNA-seq technology. After, we analyzed how 
splicing events can change the structure and function of signaling pathways 
during the differentiation of embryonic stem cells to cardiomyocytes. We looked 
closer at how different isoforms of well described cardiac genes can 
characterize different populations of cardiac progenitors: To achieve this task 
we isolated the whole transcriptome of different populations of cardiac 
progenitors in different time points of cardiac differentiation. New genes 
potentially involved in cardiogenesis were especially taken in account for this 
analysis. The main tools used in this particular systems biology task involved a 
combined application of various computational and experimental methods 
required to cope with the complexity of the studied mechanisms. 
The overall work accomplished throughout this project will allow us to better 
understand the genetic mechanisms underlying cardiogenesis for the progress 
of the science in the cardiovascular field and translational medicine. 
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2.1. Culture of mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were cultured in high glucose Dulbecco’s 
modified eagle’s medium (DMEM; Sigma, Poole, Dorset, UK) supplemented 
with 10% of fetal bovine serum (FBS), 2 mM of L-glutamine (Invitrogen Life 
Technologies, Paisley, UK), 1% non-essential amino acids (NEAA, Invitrogen 
Life Technologies) and 1% penicillin/streptomycin solution (Invitrogen Life 
Technologies). MEFs were grown in 75 cm2 flasks (Sarstedt, Leicester, UK) 
with 10 ml of media at 37°C/5% CO2 and culture media replaced every other 
day to ensure optimal growth conditions. MEF feeder layers for culture of 
mESCs were prepared using mitomycin C (Sigma). Confluent 75 cm2 flasks 
(Sarstedt, Leicester, UK) of MEFs were incubated with media containing 10 
µg/ml of mitomycin C for 2 hours at 37ºC/5% CO2 and washed 3 times with 10 
ml of PBS. Inactivated MEFs were cultured overnight or frozen before use as 
feeder cells for undifferentiated mESCs. 
 
2.2. Culture of mouse ESCs  
Mouse Nkx2.5-eGFP/SHF-dsRed (RG) ESCs were kindly provided by MD 
Ibrahim Domian. RG ESCs were cultured in knockout DMEM (Sigma) with 15% 
ESC screened FBS (Hyclone, Utah, US), 1% penicillin/streptomycin solution 
(Invitrogen Life Technologies), 2 mM L-glutamine (Invitrogen Life 
Technologies), 1% NEAA (Invitrogen Life Technologies), 0.1 mM-
mercaptoethanol (Sigma) and 1000 U/ml leukaemia inhibitory factor (LIF; 
Chemicon, Temecula, Ca, USA). RG ESCs were cultured in 60mm ø tissue 
culture specific plates with 6 mL of ESC media at 37ºC/5% CO2 and passaged 
when the ESC colonies had about 50% of confluence and before 
semiconfluency, every 2 or 3 days. The culture medium was replaced daily. 
 
2.3. Differentiation of ESCs  
RG ESCs and Ccbe1 knockdown (KD) ESCs lines were differentiated using the 
hanging droplet method previously described in the literature (Keller, 2005). 
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Undifferentiated ESCs were washed with a 1xPBS solution, then incubated with 
1xTrypsin for 2 minutes, dissociated into a single cell suspension, centrifuged 
and resuspended in fresh ESC medium without LIF. Cells were counted on 
either a hemocytometer or on an improved Neubauer chamber (VWR), and then 
a cell suspension was prepared with a final concentration of 2,2x104 cells/mL. 
Cells were plated as 20 μL drops (approximately 440 cells) onto the base of an 
anti-adherent Petri dish which was then inverted into the lid. The cells were 
cultured in hanging droplets for 48 hours (days 1 and 2). The Petri dishes were 
inverted back to the original position and 10 mL of ESC media was added to the 
plates. EBs were cultured in suspension for 4 days (days 3 to 6) before being 
plated onto gelatin (0.1%) coated wells and cultured up to day 10 of 
differentiation. Culture medium was replaced every 2 days.  
 
2.4. Fluorescent-activated cell sorting (FACS) 
EBs were gently dissociated into a single cell suspension using 1x trypsin and 
resuspended in 1xPBS. RG ESCs ran through a Becton Dickinson FACSAria II 
(BD Biosciences, Erembodegem, Belgium) using the FACSDiva 6.1.3 software 
(BD Biosciences, Erembodegem, Belgium). Flow cytometer was carried out 
upon excitation with the blue laser (488 nm) being the emission signals 
measured in the FL1 channel (530/30 nm; Green) and in the FL2 channel 
(585/42 nm; Red). Sorting was performed with a 100 µm nozzle, using a “purity” 
precision mode and a flow rate with a maximum of 10,000 events per second. In 
total, 4 different cell populations were isolated: GFP+/dsRed- FHF progenitor 
(here on named G+R-), GFP+/dsRed+ and the GFP-/dsRed+ SHF progenitors 
(here on named G+R+ and G-R+) and the GFP-/dsRed- control cells (G-R-). Cells 
were collected to anti-adherent collection tubes with fresh ESCs medium 
without LIF. To pellet the cells for RNA isolation, the collection tubes were 
centrifuged at 1000rpm and the supernatant discarded. 
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2.5. RNA extraction 
Total RNA was extracted from undifferentiated and spontaneously differentiated 
(days 0-10) ESCs. Total RNA was extracted using the TRizol Reagent 
(Invitrogen) according to the manufacturer’s instructions with the following 
modifications; cell pellets were washed with ice cold PBS before being lysed 
using 400 µL of Trizol reagent. The cell lysate was resuspended with a pipette 
several times, incubated at RT for 5 min. Chloroform (80 μL) was added to the 
lysate, the tube was mixed by inversion for about 15 seconds and centrifuged at 
13,000 rpm for 10 min. The RNA containing aqueous phase was then pipette 
into a new microtube. 10ng of RNAse-free glycogen was added to each sample 
as a carrier, to enhance the total amount of RNA extracted. Then 250 μL of ice 
cold isopropanol was mixed into the samples. The solution was then incubated 
at 30°C for 5 min before being centrifuged at 13,000 rpm for 30 min. The 
supernatant was then discarded and the pellet washed with 500 μL of icecold 
75% ethanol. After centrifugation, the supernatant was discarded and the RNA 
pellet allowed to air-dry for approximately 10 min until a tiny meniscus of 
solution was left around the pellet. Protocol was performed on ice during at all 
times and centrifugations performed at 4°C. RNA was then resuspended in 25 
μL of DNAse mix (Ambion, Life Technologies) and incubated at 37ºC for 30 
minutes. After, it was added 5 μL of DNAse inactivator, samples were 
centrifuged at 15ºC, 13.000rpm for 5 minutes, and around 22 μL of RNA was 
collected to new collection tubes. RNA concentration was determined using a 
NanoDrop® ND- 2000c Spectrophotometer (NanoDrop Technologies).  
 
2.6. RNA isolation for RNA Sequencing 
After population isolation on the FACS, the cells were pelleted by centrifugation 
at 1000 rpm and total RNA was extracted with QIAGEN’s RNeasy Micro kit, 
according to the manufacturer’s protocol. After RNA extraction, to inquiry its 
integrity, all the samples underwent an automated electrophoresis with 
ExperionTM equipment from BIO-RAD. 
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2.7. cDNA Synthesis 
The RNA was reverse transcribed using Thermo Scientific RevertAid Reverse 
Transcriptase (Fermentas). Reactions contained 1000 ng/µl of RNA, 0.5 μg of 
Oligo (dT) primer, 4 µl of 5x Reaction Buffer, 1 U/µl of RiboLock RNase 
Inhibitor, 1 mM of dNTP mixture, 10 U/µl of RevertAid Reverse Transcriptase 
and nuclease-free water (Sigma) up to 20 µl. Reactions were performed in two 
steps according to the manufacturer’s instructions. RNA and Oligo Oligo (dT) 
primers were firstly incubated at 65°C for 5 min. The remaining components 
were then added to the reaction and incubated at 42°C for 60 min followed by 
70°C for 10 minutes to denature the Reverse Transcriptase enzyme. 
 
2.8. Quantitative PCR 
The quantitative PCR (qPCR) reaction contained 2 μL of cDNA, 7.5 μL of 2x 
SsoFast Evagreen Mix (Bio-Rad), 0.33 μM of each of the forward and reverse 
primers (Invitrogen Life Technologies) and ultrapure H2O up to 15 μL.  
Reactions were performed in a CFX real-time PCR machine (Bio-Rad). Initial 
denaturation was performed at 95°C for 1minutes, followed by 40 cycles of: 
denaturation at 95°C for 15 seconds; annealing for 15 seconds (temperature 
was specific for each gene primers as specified in Table 1); and extension at 
72°C for 15 seconds. Data were acquired in the FAM/SYBR channel during the 
extension phase. The PCR product was then denaturated by progressively 
increasing the temperature from 62ºC to 99ºC (0,5ºC every 5 sec). For the 
standards, a series of 10-fold dilutions (2 x 10-4 ng/μL to 2 x 10-9 ng/μL) of the 
target-specific PCR product were generated. Reactions with an efficiency 
comprised between 90-110%, Pearson correlation coefficient close to 1 and 
melting curve without non-specific amplifications were considered for current 
application. Analyses were performed using the Bio-Rad CFX Manager 
software (version 2.1; Bio-Rad). The relative level of expression of each target 
gene was calculated using ddCq method (Bustin, 2000). Data is expressed as 
mean ± standard deviation of the mean (SEM). 
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Table 1. Primers used for Real-time PCR (qPCR) 
Gene  Forward (5’ – 3’)  Reverse (5’ – 3’)  
αMhc  GATGGCACAGAAGATGCTGA  CTGCCCCTTGGTGACATACT  
Ccbe1  GACACACGTGGACCTACCGAG  CCGTGCACTGCTGTTCACAGG  
cTnt  GGAAATCCAAGATCACTGCCTCC  GGGCACTGAGGGACAGACCA  
Esm1 TCACATACACGCCACAAAACAAC TTCCGCAAAGACCATGCAT 
Gapdh  GGGAAGCCCATCACCATCTTC AGAGGGGCCATCCACAGTCT  
Isl1  CCTGTGTGTTGGTTGCGGCA  GGGCACGCATCACGAAGTCG  
Nkx2.5  CCACTCTCTGCTACCCACCT  CCAGGTTCAGGATGTCTTTGA  
Mesp-1  TGTACGCAGAAACAGCATCC  TTGTCCCCTCCACTCTTCAG  
Vegf-C AACGTGTCCAAGAAATCAGCC AGTCCTCTCCCGCAGTAATCC 
Vegfr3 CAGACAGACAGCGGGATGGTGC AGGCTGTAGTGGGGGTGGGACA 
Pgk1  ATGGATGAGGTGGTGAAAGC  CAGTGCTCACATGGCTGACT  
Prox1 GCCATCTTCAAAAGCTCGTC  CTGGGCCAATTATCACCAGT 
 
2.9. Production of lentiviral vectors 
Commercially available shRNAs targeting codifying regions of Ccbe1 were 
purchased (Sigma) and used to produce lentiviral vectors to generate Ccbe1 
knockdown (KD) mouse ESCs lines. The shRNAs we used were named based 
on its respective commercial reference (Table 2.1). Lentiviral particules were 
produced using HEK 293T cells for the different shRNA plasmids. 
shRNA reference Sequence 
sh91779 
CCGGGAGACCGTACTGTCTGGATATCTCGAGATA
TCCAGACAGTACGGTCTCTTTTTG 
sh91780 
CCGGCCCTGACCTGTCTCATATTAACTCGAGTTA
ATATGAGACAGGTCAGGGTTTTTG 
sh91781 
CCGGCAAGTATGTCAATGGTGACAACTCGAGTTG
TCACCATTGACATACTTGTTTTTG 
Table 2.1. Sequences of the shRNAs plasmids targeting codifying regions of 
Ccbe1 used to generate the knockdown cell lines 
 
2.10. Generation of Ccbe1 knockdown mESCs lines 
RG ESCs lines expressing shRNAs against Ccbe1 mRNA were generated 
using lentiviral particles containing Ccbe1-shRNA plasmids and shRNA control 
plasmids, whose function had already been validated. RG ESCs were cultured 
in pluripotency for 2 passages prior to lentiviral infection on 60mm ø tissue 
culture plates. On the day of the infection the culture medium was replaced by 
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fresh ESCs medium LIF, the viral particles and 4 ug/mL of polybrene, 
composing a final volume of 3 mL. Cells were left to incubate for up to 6 hours, 
where after it were added additional 3 mL of fresh ESCs medium containing 
polybrene. After 24 hours the medium containing the viral particles was 
withdrawn from the plates and changed to fresh ESCs medium containing. 
Clonal selection started 48 hours after the infection protocol. To start the 
selection, puromycin was added to the ESCs medium at a final concentration of 
10 mg/mL and lasted for an additional 7 days. Newly generated clones were 
picked individually, and an initial Ccbe1 expression analysis was carried out 
through semi-quantitative PCR to assess the knockdown (KD) levels of Ccbe1. 
The clones that were confirmed to have Ccbe1 KD were then expanded and, 
two Ccbe1 KD ESCs lines and one scrambled control ESCs line (Sh-control) 
were established.  
  
2.11. Immunofluorescence in cryosections 
Cultured EBs were embedded in optimal cutting temperature (OCT), frozen at -
80 ºC, sectioned with a cryostat microtome (MARCA) (10 µm thick slices) onto 
glass slides. Frozen sections were fixed with 1% paraformaldehyde  and 
blocked with 2% bovine serum albumin and 0.02% Tween20  in PBS. Samples 
were incubated with polyclonal rabbit anti- activate caspase-3 primary antibody 
(R&D Systems, AF835; 1:500 dilution) followed by incubation with goat anti-
rabbit IgG antibody Alexa 488 (H+L; Invitrogen, A-11008; dilution 1:1000). 
Slides were mounted with Mowiol containing DAPI. 
 
2.12. Immunolabelling 
ESCs culture media was discarded and cells washed with 500 μL 1xPBS and 
dissociated with 200 μL 1x Trysin at 37ºC for 5 minutes. Then 500 μL of ESCs 
culture media was added, cells centrifuged for 5 minutes at 1000 rpm at RT and 
the supernatant discarded. Cells were resuspended in 500 μL ice-cold 1x 
PBS/3%FBS/10mM NaN3 freshly prepared, after which were centrifuged at 
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1800 rpm for 15 minutes at 4ºC. The supernatant was carefully removed with a 
P1000 micropipette, and the cells resuspended and fixed with 200μL 0,5% PFA 
in 1xPBS for 15 minutes at RT. Additionally, for washing 500  μL of ice-cold 
1xPBS/0,5% BSA/0,1% saponin were added and cells centrifuged at 1800 rpm 
for 15 minutes at 4ºC. This washing step was repeated twice after supernatant 
removal. Further on, cells were resuspended in 100 μL of 1xPBS/0,5% 
BSA/0,1% saponin containing the primary antibody and left incubating for 1 
hour at 4ºC. Washing steps were repeated twice once more. Then cells were 
resuspended in 100 μL of 1xPBS/0,5% BSA/0,1% saponin containing the 
secondary antibody and left for incubation in the dark for 1 hour at RT. Cells 
were washed one final time as described above and prior to FACS analysis 
resuspended in 500 μL ice-cold 1x PBS. The dilutions used for each antibody 
are listed in Table 3. 
 
2.13. Methylene Blue Diffusion Assay  
Cultured EBs were collected and washed in PBS before being treated with 1 
mg/mL solution of methylene blue in PBS for 10 minutes and then washed with 
PBS. Embryoid bodies were embedded in optimal cutting temperature (OCT), 
frozen at -80 ºC, sectioned with a cryostat microtome (MARCA) (10 µm thick 
slices) onto glass slides and mounted directly with DPX mountant for 
histological observation. 
 
2.14. Cell Proliferation Assay with Dye eFluor® 670 
Cultured ESCs were resuspended in PBS and counted. Cell Proliferation Dye 
eFluor® 670 (eBioscience) in PBS was added drop by drop to the cell 
suspension and incubated at 37 ºC in the dark. Labeling was stopped by adding 
cold growth medium and incubation on ice. Lastly, ESCs were washed several 
times with growth medium. ESCs were then cultured as embryoid bodies in 
hanging drops as described above.. Flow cytometry was carried out upon 
excitation with the red laser (633 nm) being the emission signals measured in 
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the FL4 channel (661/16 nm). The fluorescence intensity of the dye was 
measured along the time of culture at days 0, 2, 3, 4, 5 and 6 by flow cytometry 
and data analysed using the BD FACSDivaTM software (version 6.1.3, BD 
Biosciences). Graphics generated using FlowJo X 10.0.7r2, Tree Star, Inc. A 
total of 50.000 events were acquired for each ESC cell line. 
 
2.15. Production of Recombinant human CCBE1 protein 
HEK 293T cells grown in suspension in spinner flasks were transfected using 
standard Calcium Phosphate Method with the CCBE1 expression vector 
containing the full-length CCBE1 coding sequence followed by a 6x Histidine 
tag at the C-terminal. After 4 days of incubation, the conditioned media 
containing CCBE1 recombinant protein was loaded onto a 1 mL Histrap column 
(GE Healthcare). The bounded protein was eluted by discontinuous imidazole 
gradient and the fractions containing CCBE1 (more than 90% pure) were 
dialyzed overnight into 25 mM Tris/0.15 M NaCl/2m M CaCl2 pH7.5, then frozen 
in liquid nitrogen and kept at -80ºC until further use. 
 
2.16. Statistics 
Statistical analysis was performed using GraphPad Prism version 5.00 for 
Windows, GraphPad Software, San Diego California USA.   
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3.1. SUMMARY 
Understanding the molecular pathways regulating cardiogenesis is 
crucial for early diagnosis of heart diseases and to improve therapeutic 
approaches. During normal mammalian cardiac development, collagen and 
calcium-binding EGF domain-1 (Ccbe1) is expressed in the first and second 
heart field progenitors as well as in the proepicardium, but its role in early 
cardiac commitment remained unknown. We demonstrate that during mouse 
embryonic stem cell (ESC) differentiation Ccbe1 is upregulated upon 
emergence of Isl1- and Nkx2.5- positive cardiac progenitors. Furthermore, 
Ccbe1 is markedly enriched in Isl1-positive cardiac progenitors derived from 
embryonic stem cell differentiating in vitro as well as progenitors isolated from 
embryos developing in vivo. Ccbe1 knockdown during ESC differentiation 
resulted in impaired development of cardiac mesoderm. In addition, knockdown 
of Ccbe1 leads to reduced cell proliferation resulting in smaller embryoid 
bodies. Accordingly, blockade of CCBE1 with antibody during ESCs 
differentiation causes the same defects. Interestingly, these defects seem to be 
independent of the role of CCBE1 in the regulation of VEGF-C signaling. 
Collectively, our results indicate that CCBE1 is essential for the formation of 
cardiac mesoderm and proliferation of differentiating mouse ESCs. 
 
Keywords: Cardiac differentiation; Cell Proliferation; ESCs; Ccbe1; Cardiac 
Mesoderm.  
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3.2. INTRODUCTION 
Identification of genes and the study of their role in cardiogenesis are important 
to elucidate the molecular events regulating cardiomyocyte lineage 
commitment. This is critical for the control of cardiac commitment from different 
stem cell sources and the use of mature cardiac cells in the context of 
regenerative medicine. In a differential screen designed to identify novel genes 
required for the correct development of the heart precursor lineages Bento et al. 
(2011), we identified CCBE1, a gene coding for a secreted protein that contains 
collagen domains and a calcium binding EGF-like domain. Expression analysis 
showed that Ccbe1 is expressed in precursors of the first heart field (FHF), 
secondary heart field (SHF), and proepicardium in mice between embryonic day 
(E) 7.0 to E9.5 (Facucho-Oliveira et al., 2011). Similarly, CCBE1 was similarly 
found to be expressed in FHF and SHF populations during early chick cardiac 
development (Furtado et al., 2014). These findings implicate CCBE1 in the 
control of early cardiac commitment, but its function in this context remains 
elusive. Previous work has also shown that Ccbe1 is expressed in the 
pericardium between E11.0 and E12.5 (Bos et al., 2011), however, at these 
stages Ccbe1 is deeply involved in the development of the lymphatic system. 
Indeed, Ccbe1 loss-of-function in mice leads to prenatal death due to defective 
lymphatic vasculature (Bos et al., 2011). Ccbe1 is required for the budding and 
migration of lymphatic endothelial cells (LECs) from the anterior cardinal veins 
to give rise to the lymphatic vasculature (Bos et al., 2011; Hagerling et al., 
2013). Absence of proper lymphatic vessels results in generalized tissue edema 
by E14.5 and the mutants die shortly after. In a more recent report, it was 
demonstrated that absence of the collagen domains from CCBE1 in mice fully 
phenocopies the null mutant (Roukens et al., 2015). The mode of action of 
CCBE1 involves the recruitment of the metalloprotease ADAMTS3 
extracellularly to promote the conversion of immature (Pro-)VEGF-C into its 
mature and fully active pro-lymphangiogenic form (Jeltsch et al., 2014; Le Guen 
et al., 2014).  
In humans, mutations in CCBE1 have been associated with Hennekam 
syndrome (HS), a disorder characterized by abnormal lymphatic system 
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development. Interestingly, some patients also present with congenital heart 
defects including hypertrophic cardiomyopathy and ventricular septal defects 
(Alders et al., 2009; Connell et al., 2010; Connell et al., 2012), consistent with a 
role of CCBE1 during heart formation. Although two recent studies suggest that 
cardiac development is normal in Ccbe1 mutant mice (Burger et al., 2015; 
Jakus et al., 2014), we showed that CCBE1 is required for the migration of the 
cardiac precursor cells to form the heart tube during chicken heart development 
(Furtado et al., 2014). Modulation of CCBE1 levels in the chick embryos leads 
to cardia bifida when the cardiac fields are exposed to high levels of CCBE1. 
Conversely, exposure to low levels of CCBE1 result in incorrect fusion of the 
bilateral cardiac fields to form the heart tube.. Therefore, given those opposing 
observations about the role of CCBE1 in the development of the heart from 
different species, we sought to study the role of CCBE1 during cardiogenesis 
using an established model of cardiac differentiation in vitro using mouse ESCs.  
Here, we analyzed the effect of Ccbe1 loss-of-function during 
differentiation of mouse ESCs and identified a role in early cardiac mesoderm 
commitment as well as in cell proliferation. In addition, we examined Ccbe1 
expression in differentiating mouse ESCs and confirmed its expression in 
isolated cardiac progenitor populations derived from ESCs. 
 
3.3. RESULTS 
High Ccbe1 expression coincides with the appearance of cardiac 
progenitors 
To evaluate Ccbe1 expression during cardiac differentiation, we exploited the 
double transgenic RG ESC line, wherein the red fluorescent protein dsRed is 
under the control of the second heart field (SHF) enhancer of Mef2C, and the 
enhanced green fluorescent protein (GFP) is under the control of the cardiac-
specific enhancer of Nkx2.5 (Domian et al., 2009). This ESC line allows for the 
isolation of pure populations of FHF (GFP+/dsRed- or G+R-) and SHF 
(GFP+/dsRed+ or G+R+, and GFP-/dsRed+ or G-R+) progenitors by FACS. 
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 Mouse RG ESCs were differentiated as embryoid bodies using the 
hanging droplets method and samples collected every 48 hours to examine 
Ccbe1 expression by quantitative PCR (qPCR). Cardiac specific genes 
including Mesp-1, Isl1, Nkx2.5, αMhc and cTnt, were then assayed as markers 
of cardiac differentiation. Expression analysis showed high levels of Mesp-1 at 
day 4 of differentiation (Figure 3.1B) consistent with the formation of cardiac 
mesoderm. The expression of the cardiac mesoderm and SHF marker Isl1 
increased considerably at day 4 and peaked at day 6, while the general cardiac 
progenitors and primitive cardiomyocyte marker Nkx2.5 increased only at day 6 
(Figure 3.1C-D). The appearance of Isl1 expression at day 4, prior to Nkx2.5, is 
consistent with the in vivo situation where Isl1 expression precedes Nkx2.5 
expression during the formation of cardiac mesoderm (Laugwitz et al., 2008). 
The cardiomyocyte markers cTnt and αMhc were first expressed at day 6 with 
peak expression at day 10 (Figure 3.1E-F). Analysis of Ccbe1 expression 
revealed similar levels of Ccbe1 in undifferentiated mouse ESCs and days 2 
and 4 of differentiation (Figure 3.1A). Higher Ccbe1 expression was detected at 
day 6 of differentiation, concurrent with peak of expression of cardiac progenitor 
 
Figure 3.1 - Expression of (A) Ccbe1, (B) Mesp-1, (C) Islet1, (D) Nkx2.5, (E) αMhc, 
and (F) cTnt during differentiation of mouse ESCs. Samples were collected from 
undifferentiated cells (Und) and at days 2, 4, 6, 8 and 10 of differentiating RG mouse 
ESCs. Expression is presented as fold change relative to undifferentiated cells. Data 
represent the mean + SEM of two biological replicates in technical qPCR triplicates. 
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marker Isl1 and the increasing expression of Nkx2.5. At days 8 and 10, Ccbe1 
was highly expressed but not as high as day 6. This suggests that in embryonic 
stem cells differentiating in vitro, like mouse embryos developing in vivo 
(Facucho-Oliveira et al., 2011), the appearance of high levels of Ccbe1 
expression coincide with the formation of FHF and SHF cardiac progenitors. 
 
Ccbe1 is expressed in SHF and proepicardium cardiac progenitors  
In order to confirm that the increase in Ccbe1 expression is associated 
with the formation of FHF (G+R-) and SHF (G+R+ and G-R+) cardiac progenitor 
cells, we isolated these populations by FACS and analyzed Ccbe1 expression 
along with Isl1 and Nkx2.5 expression to confirm the identity of the isolated 
populations. Expression analysis revealed Ccbe1 transcripts in all cardiac 
progenitor populations (Figure 3. 2A-C). At day 6, Ccbe1 expression was higher 
(3.8 fold) in SHF G-R+ cardiac progenitor cells or SHF-derived cells compared to 
 
Figure 3.2 - Ccbe1 expression in cardiac progenitors isolated from 
differentiating mouse ESCs and embryos at E9.5. Expression was analyzed in 
isolated populations, defined as FHF G+R- population, SHF G+R+ and G-R+ 
populations and control G-R- population at (A) day 6, (B) day 8 and (C) day 11 from 
differentiating mouse ESCs, and from (E) E9.5 mouse embryos. Expression is 
represented as fold change relative to the control G-R- population. (D) Analysis of 
Ccbe1 in the control G-R- population at day 6, 8 and 11 relative to the expression at 
day 6. The identity of the sorted populations at day 6 was confirmed by analyzing 
the expression of (F) Ist1 and (G) Nkx2.5. Mean + SEM of two biological replicates. 
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the double negative control (Figure 3.2A). In contrast, Ccbe1 expression was 
down regulated in SHF G+R+ and FHF G+R- cardiac progenitors when 
comparing to the same control population.. Interestingly, a very similar Ccbe1 
expression profile was observed in FHF and SHF progenitors isolated from 
mouse embryos at E9.5 (Figure 3.2E). Ccbe1 was also enriched in the 
equivalent SHF G-R+ population isolated from Nkx2.5-GFP/SHF-dsRed 
transgenic mouse embryos (2.5 fold). Isl1 and Nkx2.5 expression is consistent 
with the identity of the sorted populations from mouse RG ESCs at day 6 of 
differentiation (Figure 3.2F-G). 
At day 8 of ESC differentiation, the G-R+ cells continue to have higher 
Ccbe1 expression than the G+R+ and G+R- progenitors (Figure 3.2B). However, 
Ccbe1 expression in the SHF G-R+ population was similar to the expression in 
control G-R- population, likely due to the emergence of non-cardiac cell types 
(G-R-) that also express high levels of Ccbe1 (Figure 3.2E). Ccbe1 has been 
previously shown to be expressed in the dermamyotome of the somites and in 
cells located in the vicinity of the anterior cardinal veins between stages E8.75 
and E10.5 mouse development (Facucho-Oliveira et al., 2011). At day 11, 
Ccbe1 was mainly observed in the G+R+ population (Figure 3.2C). This is likely 
related with the formation of proepicardium progenitors, which are known to 
derive from Nkx2.5+/Isl1+ cells at the lateral zone of the cardiogenic mesoderm 
(Mommersteeg et al., 2010; Zhou et al., 2008) and were also shown to express 
Ccbe1 in mouse embryos (Facucho-Oliveira et al., 2011). Taken together, these 
results show that Ccbe1 expression in differentiating mouse ESCs is concurrent 
with the appearance of specific populations of cardiac progenitors. 
 
Ccbe1 knockdown leads to reduced cardiac mesoderm formation from 
differentiating ESCs 
The presence of Ccbe1 early on in both mouse ESC derived and mouse 
embryonic cardiac progenitors led us to hypothesize that Ccbe1 could have a 
role during establishment or maintenance of cardiac progenitors. To test this, 
we generated transgenic mouse ESC lines expressing shRNAs targeting Ccbe1 
and evaluated the effect of Ccbe1 loss-of-function in ESC-derived cardiac 
differentiation. Ccbe1 KD ESC clonal lines were generated by lentiviral 
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transduction using RG as WT line. We carried out spontaneous differentiation of 
two individual Ccbe1 KD ESC clones (Clone 1 and Clone 2) in comparison to 
the SH control ESC line to exclude off target effects of the shRNAs. Analysis of 
Ccbe1 expression in undifferentiated cells confirmed significant Ccbe1 
downregulation in Clone 1 and Clone 2 when compared to the Ccbe1 levels 
found in the control line (Figure 3.3A). At days 2 and 4 of differentiation, Ccbe1 
expression was also reduced when compared to that of the Control line, but 
was only statistically significant at day 4 (Figure 3.3A). Additionally, when 
Ccbe1 expression normally peaks at day 6 of differentiation (Figure 3.1A), KD 
ESCs showed a very strong reduction in the expression of Ccbe1 (Figure 3.3A). 
Together, this data confirm that knockdown of Ccbe1 was maintained during the 
in vitro differentiation of both cell lines. 
To understand if Ccbe1 knockdown affects the pluripotency of mouse 
ESCs, we analyzed the expression of the pluripotency markers like Sox2, Oct4 
and Nanog. According to our analysis, expression of Oct4 and Sox2 was not 
affected in both KD ESC lines (Figure 3.3B). However, Nanog expression was 
significantly reduced in both clones. It is known that Nanog expression normally 
oscillates in pluripotent mouse ESC cultures and that ESCs with lower Nanog 
expression are more prone to differentiate but without any lineage bias 
(Abranches et al., 2014; Chambers et al., 2007). In agreement with this, 
expression of the early ectodermal marker Fgf5, of the endodermal marker Afp 
and of the mesoderm marker BraT were not significantly different in 
differentiating SH control ESCs and both Ccbe1 KD ESC lines (Figure 3.3B). 
This suggests that, even though Nanog is downregulated, the Ccbe1 KD ESCs 
retain the pluripotency and trilineage differentiation capacity. 
We then showed that expression of cardiac mesoderm markers Mesp1 
and Isl1 was markedly reduced both in Clone 1 and Clone 2 at day 4 of 
differentiation (Figure 3.3B). In addition, expression of Nkx2.5 was also reduced 
in both differentiated Ccbe1 KD clones. These data suggest that in the absence 
of Ccbe1, ESCs have reduced capacity to differentiate towards the Mesp1 and 
Isl1 cardiogenic mesoderm lineage. This in turn results in a reduction of Nkx2.5-
expressing cardiac progenitor cells. Surprisingly, at day 6 of differentiation, 
expression of the cardiac precursor marker Nkx2.5 was seemingly not affected, 
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Figure 3.3 - Ccbe1 knockdown leads to reduced cardiac mesoderm formation from 
differentiating mouse ESCs. (A) qPCR analysis of Ccbe1 up to day 6 of differentiation; (B) 
qPCR analysis at Day 0 of pluripotency markers Oct4, Nanog and Sox2, at Day 2 of the germ 
layer markers Fgf5, Afp and BraT; at Day 4 of the cardiac precursor markers Mesp1 and Isl1, and 
Nkx2.5; and at Day 6 of the cardiac markers Isl1, Nkx2.5, cTnt and aMhc. Analysis was 
performed in two individual Ccbe1 KD ESC clones (Clone 1 and Clone 2) and compared to SH 
Control. Mean ± SEM of three biological replicates in technical qPCR triplicates; paired t-test 
relative to SH Control group; statistical significance * p<0.05, ** p<0.01, *** p<0.001 
 
 
and Isl1 was downregulated only in clone 2 (Figure 3.3B). In the case of the 
early cardiomyocyte markers αMhc and cTnt there was a slight reduction in both 
Ccbe1 KD clones, which could indicate that differentiation towards mature 
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cardiomyocytes is reduced in the absence of Ccbe1. Therefore, even though at 
day 4 of differentiation there was a decrease in the Mesp1- and Isl1-expressing 
cardiac mesoderm, at day 6 the Nkx2.5-expressing cardiac precursors were 
established in a seemingly normal proportion. However, morphological analysis 
of the embryoid bodies revealed that by the third day of differentiation the 
embryoid bodies derived from both Ccbe1 KD ESC lines were slightly smaller 
when compared to the embryoid bodies derived from the parental line wild type 
(WT) RG or SH Control lines (Figure 3.4A). This phenotype was more evident at 
day 4 of differentiation. By day 5 that the embryoid bodies derived from Ccbe1 
KD ESCs lines were roughly half the size of the WT and SH controls (Figure 
3.4A). Since the number of cells in the embryoid bodies can affect differentiation 
(Nakazawa et al., 2013; Zeng et al., 2013), we cannot exclude that the effect on 
the proportion of cardiac precursors by day 6 of differentiation in those clones is 
a consequence of the observed paucity in the embryoid bodies from derived 
from the KD ESC clones. Nevertheless, together these data suggest that Ccbe1 
is essential for the formation of ESC-derived Mesp1- and Isl1-expressing 
cardiac mesoderm and for proper growth of the embryoid bodies. 
The defects induced by the knockdown of Ccbe1 are CCBE1 specific 
To confirm that it was indeed the absence of Ccbe1 that led to the 
phenotype observed on the differentiating ESCs, two different strategies were 
conducted. On the one hand, we supplemented the WT RG ESCs during 
differentiation with CCBE1 antibody to function as a blocking antibody. We 
cultured the ESCs up to day 5 of differentiation in the presence of 100 ng/mL 
CCBE1 antibody in the differentiation medium or with the equivalent amount of 
buffer used as the control.  
As shown in Figure 3.4B, supplementing the culture medium with CCBE1 
antibody led to a significant decrease on the size of the embryoid bodies 
derived from WT ESCs by day 5 of differentiation. Furthermore, analysis of 
Mesp-1 and Isl-1 expression in ESCs treated with CCBE1 antibody showed that 
their expression was also downregulated (Figure 3.4C), similarly to what was 
observed in the differentiating Ccbe1 KD ESCs (Figure 3B, Day 4). These data 
are consistent with the phenotype observed in the differentiating ESCs being 
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specifically caused by Ccbe1 loss-of-function. On the other hand, we 
supplemented the Ccbe1 KD ESCs during differentiation with exogenous full 
length CCBE1 protein. Since CCBE1 is a secreted protein, ESCs could be 
cultured up to day 5 of differentiation in the presence of 200 ng/mL of 
 
Figure 3.4 - Ccbe1 loss-of-function leads to smaller embryoid bodies. Phase-
contrast micrographs of Ccbe1 KD ESC-derived embryoid bodies and controls (A) at 
days 3, 4 and 5 of differentiation. Graphs at the right side show the corresponding 
diameter measurements of embryoid bodies at days 4 and 5 of differentiation; (B) 
Phase-contrast micrographs of WT ESCs derived embryoid bodies at days 3, 4 and 5 of 
differentiation with and without supplementation of 100ng/mL of CCBE1 antibody. Graph 
on the right side shows the corresponding diameter measurements of the embryoid 
bodies at day 5 of differentiation;  unpaired t-test relative to non supplemented group; 
statistical significance p<0.001; Scale-bars: 200 µm; (C) qPCR analysis of cardiac 
precursor markers at day 4 of differentiation. Data represent the mean ± SEM of three 
biological replicates in technical qPCR triplicates; paired t-test relative to SH Control 
group; statistical significance * p<0.05, ** p<0.01, *** p<0.001  
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recombinant CCBE1 protein in the differentiation medium or with the equivalent 
volume of buffer used as the control.  
As shown in Figure 3.5A-B, supplementing the culture medium with 
recombinant CCBE1 protein led to a fair increase on the size of the embryoid 
bodies derived from the Ccbe1 KD ESC lines by day 5 of differentiation, more 
evident in the case of clone 2. This suggests that treatment with exogenous 
CCBE1 rescues the phenotype, but since the rescued embryoid bodies are still 
smaller than in the case of the WT and SH Control lines, and the fact that the 
 
Figure 3.5 - Recombinant CCBE1 partially rescues the defects caused by the 
loss of Ccbe1. Phase-contrast (A) Phase-contrast micrographs of Ccbe1 KD ESC-
derived embryoid bodies and controls with supplementation of 200ng/mL recombinant 
CCBE1 or with buffer control, at day 5 of differentiation. Scale-bar: 200µm. (B) A 
partial rescue on the size of the Ccbe1 KD embryoid bodies is observed at this stage 
of differentiation. (C) qPCR analysis of cardiac precursor markers at day 4 of 
differentiation. Data represent the mean ± SEM of two biological replicates in technical 
qPCR triplicates; paired t-test relative to SH Control group; statistical significance * 
p<0.05, ** p<0.01, *** p<0.001. 
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cardiac mesoderm markers are still downregulated (Figure 3.5C), it is 
suggested that the rescue is only partial. This corroborates however that the 
phenotype observed in the differentiating Ccbe1 KD ESCs is indeed caused by 
knockdown of Ccbe1. 
Ccbe1 KD decreases the proliferation of differentiating ESCs 
Next, we addressed the cellular mechanism causing the impaired growth of the 
Ccbe1 KD ESC-derived embryoid bodies. While increased cell death and/or 
reduced proliferation are probable causes, another hypothesis is that the dense 
shell-like outer layer normally present in embryoid bodies, which secretes 
morphogens essential for mesoderm and cardiac mesoderm formation 
(Coucouvanis and Martin, 1999; Sachlos and Auguste, 2008), could be absent 
in Ccbe1 KD embryoid bodies. It has been shown that absence of this dense 
shell-like layer, described as resembling the visceral endoderm of developing 
mouse embryos, caused by the blockade of collagen/β1-integrin interaction in 
mouse induced pluripotent stem cell (miPSC)- derived embryoid bodies affects 
both the size of embryoid bodies and cardiac differentiation (Zeng et al., 2013). 
Since CCBE1 is an extracellular protein with collagen domains, we decided to 
test if this dense outer layer was properly established in Ccbe1 KD ESC-derived 
embryoid bodies. To test this, we performed a methylene blue (Mb) diffusion 
assay. Embryoid bodies were incubated with 1 mg/mL solution of Mb, and 
depending on the presence or absence of the visceral endoderm-like layer, the 
embryoid bodies should accumulate Mb at the surface or present a 
homogenous staining, respectively. According to our analysis and like in the 
controls, the staining accumulates at the surface of the Ccbe1 KD ESC-derived 
embryoid bodies at all stages (Figure 3.6A). This indicates that the dense outer 
shell-like layer resembling the visceral endoderm is present in the absence of 
Ccbe1.  
To understand whether the knockdown of Ccbe1 affects cell viability in 
differentiating ESCs, we evaluated caspase-3 mediated apoptosis and cell 
proliferation. As shown in Figure 3.6B, immunofluorescence staining from 
cryosectioned embryoid bodies showed no obvious differences on the number 
of cleaved caspase-3 positive cells between control and Ccbe1 KD ESC-
derived embryoid bodies. Quantification of the percentage of apoptotic cells by 
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immunolabelling against cleaved caspase-3 followed by FACS at days 4 and 5 
of differentiation confirmed that there were no differences between Ccbe1 KD 
ESC-derived embryoid bodies and controls (Fig. 3.6C). This suggests that cell 
 
Figure 3.6 – Visceral endoderm-like layer is present and cell death is not affected in 
the absence of Ccbe1. (A) Methylene blue (Mb) diffusion assay. Bright-field micrographs of 
cryosectioned embryoid bodies at days 3, 4 and 5 of differentiation. The dark blue staining 
surrounding the surface confirms the presence of the dense outer shell-like layer in both 
controls and in the Ccbe1 KD ESC-derived embryoid bodies at all stages. Accumulation of 
Mb at the surface is caused by the presence of extracellular matrix proteins (ECM) 
synthesized by the visceral endoderm-like layer creating a physical barrier to the dye. (B) 
Micrographs of active caspase-3 immunofluorescence staining of cryosectioned embryoid 
bodies at day 4 of differentiation. The Green channel marks the active caspase3 positive 
cells, and the blue channel marks for DAPI. Scale-bar: 50µm. (C) Quantification of 
immunolabelled CASP-3 positive cells analyzed by FACS at days 4 and 5 of differentiation.  
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death cannot explain the smaller size of the embryoid bodies in the absence of 
Ccbe1.  
Next, we performed a proliferation assay consisting of labelling the ESCs 
with nuclear proliferation dye eFluor® 670 and analyzing the fluorescence 
decay dependent on cell division for the following 6 days of differentiation. At 
day 0 the ESC were equally labeled, the cells presented the highest 
fluorescence and hence all cells locate at quadrant (Q)1 (Figure 3.7A). At the 
second day, all the cells located at Q2, indicating that the cells from all 
individual lines divided in a similar manner (Figure 3.7B). At day 3 of 
differentiation, while the fluorescence decay continued gradually in WT and SH 
control lines, the clone 2 presented a delay suggesting a decreased proliferation 
rate (Figure 3.7C). At day 4 both Ccbe1 KD differentiating ESCs showed a 
higher percentage of cells in Q2 when compared to the controls (Figure 3.7D), 
indicating that the proliferation rate of both lines was decreased. At days 5 and 
6 this difference was more pronounced (Figure 3.7E-F), where most of the 
differentiated ESCs from the control lines had lost all the fluorescence (Q4 – 
73%), but the differentiating ESCs from Clone 1 and 2 had more cells remaining 
in Q2 35% and 43%, and in Q3 51% and 26% respectively. This data strongly 
suggests that knockdown of CCBE1 results in a reduction in the proliferation of 
progenitors by days 5 and 6 of differentiating Ccbe1 KD ESC lines. This 
observation is consistent with the observed smaller size of the embryoid bodies 
derived from both Ccbe1 KD clones (Figure 3.4A). In contrast, in pluripotency 
there were no differences in the proliferation between control and Ccbe1 KD 
ESC lines (data not shown). Taken together, these data indicate that 
knockdown of Ccbe1 leads to decreased proliferation of differentiating ESCs, 
which becomes striking between day 4 and day 6 of differentiation. 
 
CCBE1 functions in a VEGF-C/VEGFR3 independent signaling pathway 
during cardiac differentiation. 
During lymphangiogenesis, CCBE1 is required to facilitate the maturation of 
Pro-VEGF-C into its mature form (Jeltsch et al., 2014; Le Guen et al., 2014). 
Even though VEGF-C is indisputably involved in the migration of LECs during 
lymphangiogenesis, in other contexts it has also been shown to regulate cell 
proliferation (Dias et al., 2002; Shin et al., 2002). This prompted us to determine 
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if Vegf-C was normally expressed during ESC differentiation and, if the 
observed defects in Ccbe1 KD ESCs lines can be rescued by mature 
recombinant VEGF-C. Gene expression analysis confirmed the expression of 
 
Figure 3.7 - Ccbe1 knockdown decreases the proliferation of differentiating ESCs. 
Cell Proliferation Assay with dye eFluor® 670 analysed by FACS. Colored histograms 
represent the cell count for each ESC line: (1) WT Control (dark blue), (2) SH Control (light 
blue), (3) Clone 1 (dark red) and (4) Clone 2 (orange). Histograms were divided into four 
quadrants (Q1-Q4) according to the decreasing fluorescence of the controls, along the six 
different time points: (A) day 0, (B) day 2, (C) day 3, (D) day 4, (E) day 5 and (F) day 6 of 
differentiation. The maximum fluorescence corresponds to Q1, while no fluorescence 
corresponds to Q4. The bar-graphs represent the percentage of cells distributed in each 
quadrant for each ESC line. Two biological replicates were performed. 
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Vegf-C and its receptor Vegfr3 during WT mouse ESCs differentiation with 
higher expression levels of Vegf-C appearing at days 4 and 5 of differentiation 
(Figure 3.8A). This is in agreement with the identified expression of Vegf-C in 
mouse embryos as early as E7.0, when the different early mesoderm 
progenitors are being established (Kukk et al., 1996). Furthermore, this time 
point coincides with the onset of the phenotypes observed in the differentiating 
Ccbe1 KD ESCs. Interestingly, at days 4 and 5 of differentiation, Vegf-C was 
downregulated in both Ccbe1 KD clones and in ESCs supplemented with 
antibody against CCBE1 when compared to the respective controls (Figure 
3.8B-C). This could be an indication that the phenotypes observed in the 
absence of Ccbe1 were related to reduced VEGF-C signaling. This prompted us 
to supplement differentiating Ccbe1 KD ESC with 100 ng/mL of mature 
recombinant VEGF-C. However, mature VEGF-C supplementation did not 
rescue the growth of EBs, nor the expression of Mesp1 and Isl1 cardiac 
mesoderm markers in the differentiation KD clones (Figure 3.8D-E). Moreover, 
Esm1 and Prox1, two known targets of the VEGF-C signaling during 
lymphangiogenesis (Shin et al., 2008), were not significantly altered upon 
supplementation with mature recombinant VEGF-C (Figure 3.8E). Collectively, 
these results suggest that, despite the expression of Vegf-C and its receptor, 
VEGF-C signaling is not required for CCBE1 activity during cardiac 
differentiation. Thus, CCBE1 acts independently of VEGF-C signaling during 
cardiac mesoderm commitment and cell proliferation of differentiating ESCs 
3.4. DISCUSSION 
We here show that like mouse and chick embryonic cardiac development 
(Facucho-Oliveira et al., 2011; Furtado et al., 2014), Ccbe1 is upregulated in 
SHF cardiac progenitors derived from ESC differentiating in vitro. Thus, high 
Ccbe1 expression is correlated with the onset of cardiac specification both in 
vivo and in vitro. In addition, disruption of normal CCBE1 activity by shRNA 
knockdown or by blocking antibody results in a clear decrease in the expression 
of the early cardiac mesoderm markers Mesp1 and Isl1 at day 4. These results 
show that CCBE1 is required for the normal development of early cardiac 
precursors. 
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Figure 3.8 – Defects caused by the absence of Ccbe1 seem unrelated to the role of 
CCBE1 in VEGF-C maturation. (A) Expression of Vegf-c and Vegfr3 in differentiating 
ESCs; (B) qPCR analysis of Vegf-c in Ccbe1 KD ESC clones and SH Control at days 4 and 
5 of differentiation; (C) qPCR analysis of Vegf-c in WT embryoid bodies supplemented with 
100ng/mL of CCBE1 antibody; (D) Embryoid bodies diameter measurements at day 5 of 
differentiation after supplementation with 100ng/mL of mature VEGF-C; paired t-test relative 
to non supplemented groups; no statistical significance is present. (E) qPCR analysis of 
cardiac precursor markers Mesp1 and Isl1, and of downstream targets of VEGF-C signaling 
Prox1 and Esm1 at day 4 of Ccbe1 KD ESC differentiation upon supplementation or not 
with 100ng/mL of mature VEGF-C; Data represents the mean ± SEM of three biological 
replicates in technical qPCR triplicates; paired t-test relative to SH Control group; statistical 
significance * p<0.05, ** p<0.01, *** p<0.001   
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The developmental fate of differentiating ESCs depends on embryoid body size, 
growth factor signaling, ECM proteins that constitute the developmental nich 
and how ESCs interact with this niche (Bratt-Leal et al., 2009; Czyz and Wobus, 
2001; Goh et al., 2013; Higuchi et al., 2013; Taylor-Weiner et al., 2013; Zeng et 
al., 2013). We show here that in the absence of Ccbe1, the growth of 
differentiating embryoid bodies was arrested especially from day 4 onwards. 
This impaired embryoid body growth is caused by reduced cell proliferation and 
not by cell death, nor by the absence of the outer endoderm-like layer. 
Therefore, it is possible that the reduced proliferation rate of Ccbe1 KD ESCs 
differentiating in vitro could influence cardiac mesoderm commitment. 
Nevertheless, the size of the embryoid bodies treated with CCBE1 blocking 
antibody was preserved at day 4 and was only slightly reduced at day 5. In 
contrast, the expression of the cardiac precursor markers was markedly 
diminished during the same time period. This indicates that the cardiac 
mesoderm commitment phenotype is Ccbe1 dependent and is not primarily 
related to the size of the embryoid bodies. The effect of reduced embryoid body 
size seems to be more critical from day 5 onwards, coinciding with the time that 
cell proliferation is more severely affected and embryoid bodies are strikingly 
smaller. From this time point onwards most alterations in gene expression may 
be related to the reduced size of the embryoid bodies and consequent 
alterations in the microenvironment of the cells. Therefore, our data suggests 
that, besides its role during early cardiac commitment, Ccbe1 may have an 
independent role in the proliferation of differentiating ESCs.  
In mice, Ccbe1 loss-of-function results in embryonic lethality at E14.5 
due to lymphangiogenesis defects (Bos et al., 2011). Indeed, CCBE1 has been 
implicated in the modulation of VEGF-C signaling during mammalian 
lymphangiogenesis (Bos et al., 2011; Hagerling et al., 2013) and zebrafish 
lymphangiogenesis (Astin et al., 2014; Hogan et al., 2009; Le Guen et al., 
2014). In that context, CCBE1 recruits the metalloprotease ADAMTS3 to 
promote the in situ maturation of pro-VEGF-C into a mature lymphangiogenic-
promoting form, thereby activating the downstream signaling pathway (Jeltsch 
et al., 2014; Le Guen et al., 2014). Interestingly, in vitro studies have also 
shown that VEGF-C regulates cell proliferation in contexts other than 
lymphangiogenesis (Dias et al., 2002; Shin et al., 2002). The only function 
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described so far for CCBE1 is on the maturation of VEGF-C. Furthermore 
expression of Vegf-C was downregulated in the Ccbe1 KD ESCs. We therefore 
hypothesized that the cell proliferation and cardiac mesoderm commitment 
defects caused by the silencing of Ccbe1 could be related to Vegf-C maturation. 
However, mature recombinant VEGF-C did not rescue the Ccbe1 KD 
phenotype with respect to embryoid body size or expression of cardiac 
mesoderm markers Isl1 and Mesp1. In the experiments with the Ccbe1 KD 
clones, this downregulation could be somewhat related to the reduced size of 
the embryoid bodies. However, as mentioned above, the WT embryoid bodies 
supplemented with the CCBE1 antibody had preserved size at day 4 of 
differentiation, but still showed the downregulation of the cardiac mesoderm 
markers and Vegf-C. Therefore, it is possible that the downregulation of Vegf-C 
is more directly related with the absence of Ccbe1, like in the case of the 
cardiac mesoderm markers, or with problems in the specification of a particular 
cell population that could express Vegf-C. Contrasting with this, supplementing 
the differentiating Ccbe1 KD ESCs with full-length recombinant CCBE1 led to a 
fair rescue the size of the EBs. Therefore this suggests that the defects caused 
by the disruption of Ccbe1 are likely independent of the molecular mechanism 
involving VEGF-C signaling. Nonetheless, since the supplementation with full-
length recombinant CCBE1 does not rescue the expression of the cardiac 
mesoderm markers when Ccbe1 is downregulated, one cannot exclude that in 
its role in early cardiac specification, CCBE1 can synergistically interact with 
additional growth factors which expression may also be affected.  
During mouse development, the expression of Vegf-C can be detected in 
the embryo as early as E7.0 (Kukk et al., 1996), which corresponds to days 4 
and 5 of ESCs differentiation, and correlates with our expression analysis. 
However, it is only around E8.5 that Vegfr3 starts to be expressed in mice (Kukk 
et al., 1996), and lymphangiogenesis is triggered around E9.0 when the first 
LECs start to differentiate from blood endothelial cells (Francois et al., 2008). 
Prior to that stage, there is no obvious role appointed to VEGF-C/VEGFR3 
signaling pathway. In agreement with this, when supplementing differentiating 
ESCs with mature recombinant VEGF-C, the two downstream targets of VEGF-
C signaling Esm1 and Prox1 remained unaltered despite the presence of 
VEGFR3 at those stages. Therefore, this suggests that those target genes 
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induced during lymphangiogenesis are not activated by VEGF-C signaling 
during early ESC differentiation or, alternatively, that the ESCs at those 
differentiation stages may not respond to VEGF-C signaling. Reports where 
similar experiments with supplementation of mature VEGF-C during ESCs 
differentiation were performed showed that VEGF-C influenced differentiation 
much later during differentiation in a lymphangiogenesis-like process (Liersch et 
al., 2006; Mishima et al., 2007). Therefore, our data is in agreement with the 
defects in cell proliferation and cardiac mesoderm commitment being caused by 
the absence of CCBE1 and independent of its role in VEGF-C maturation.  
In vivo, Ccbe1 is expressed at later stages of mammalian cardiac 
development (Facucho-Oliveira et al., 2011), and both chick embryos and HS 
patients present cardiac defects when CCBE1 is disrupted (Alders et al., 2009; 
Connell et al., 2010; Connell et al., 2012; Furtado et al., 2014). Therefore, it 
would be interesting to study if Ccbe1 has a role at later stages of ESCs cardiac 
differentiation. One possibility would be to study the disruption of the gene at 
specific time points later during cardiac commitment in differentiating ESCs. 
This would allow us to evaluate whether the modulation of Ccbe1 can contribute 
in vitro to the full maturation of cardiac progenitors and/or beating 
cardiomyocytes. 
Taken together, our data indicates that during ESC-derived cardiac 
differentiation Ccbe1 is required to promote cell proliferation and the formation 
of cardiac mesoderm precursor cells. 
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4.1. SUMMARY 
The identification of genetic signatures of specific cells populations enables 
their isolation for transplantation in patients, and/or disease treatments in 
regenerative medicine applications. Here we aimed at investigating some of the 
genetic networks underlying embryonic cardiogenesis to identify novel genes or 
isoforms. Firstly, we isolated from differentiating ESCs a sub-population of 
cardiac progenitor cells and collected good quality RNA. After, we identified by 
RNA sequencing – a whole-transcriptome screening analysis – significant 
differential expression for 3 potentially novel cardiogenesis-associated genes, 
namely Asb2, Cck and 3632451O06Rik.  
KEYWORDS: Stem cells; Cardiac progenitors; Heart development; First heart 
field; Second heart field; RNA-seq; Transcriptome; Functional enrichment 
analysis. 
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4.2. INTRODUCTION 
Vast arrays of genes and signalling pathways have been reported to be crucial 
in all steps of cardiogenesis, whether we refer to in vivo or in vitro models. 
When the cardiac mesoderm specification occurs, different early cardiac 
markers start to be expressed, such as Nkx2.5, Isl1, Gata4 and Tbx18 
(reviewed in Meilhac et al., 2014), and such markers are also found to be 
expressed in differentiating pluripotent stem cells (PSCs; Laflamme and Murry 
2011).  
During the embryonic development there are mainly two pools of progenitor 
cells that give rise to the heart – the first heart field (FHF) and the second heart 
field (SHF). These progenitors have only recently been described in mouse 
ESCs (Domian et al., 2009). These authors generated a double transgenic 
mouse ESC line, wherein the red fluorescent protein dsRed is under the control 
of the SHF enhancer of Mef2C, and the enhanced green fluorescent protein 
(eGFP) is under the control of the cardiac-specific enhancer of Nkx2.5. With the 
expression of these fluorescent markers it was possible to isolate, in developing 
hearts and differentiating ESCs, the cell populations expressing one, both or 
none of these reporters, corresponding to the sub-populations of the FHF, SHF 
and non-cardiac control cells.  
This cell line is a good model for embryonic cardiogenesis and a powerful tool 
to study the divergent genetic origin of the different cardiac progenitor 
populations, which supports our choice to work with this double transgenic ESC 
line, where we performed RNA sequencing (or simply RNA-seq) in order to 
analyze the transcriptome of each cell sub-population. This allows the 
quantification of gene expression in a genome-wide fashion and in a given 
moment in time, representing an additional way of identifying novel genes or 
growth factors that regulate cardiogenesis. Additionally, it enables the discovery 
and identification of putative isoforms of well-known cardiac genetic players, as 
well as the analysis of how their expression changes with time within the same 
cell population, and between populations from the same differentiation time 
point. 
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4.3. RESULTS 
Isolation of different cardiac progenitor populations and RNA collection, 
integrity control and quality analysis 
Differentiating the double transgenic ESCs line, here on referred as RG, 
allowed the isolation of pure populations of FHF (G+R-) and SHF (G+R+ and G-
R+) progenitors by fluorescence-activated cell sorting (FACS). ESCs were 
cultured as embryoid body aggregates (EBs) as described before, and cell 
suspensions were prepared at days 4 and 6 of differentiation to isolate the 
populations of cardiac progenitor cells under FACS. Prior to sorting, cell 
complexity and viability was taken into account to set the scatter gate, and the 
sorting gates established for cell sorting were adjusted as described in the 
literature (Figure 4., upper left panel; Domian et. al 2009). Indeed, this approach 
granted the successful isolation of the four individual cell populations. The 
upper right panel of Figure 4.1 indicates that according to the gates described, 
on day 4 of differentiation the G+R- isolated population (gate P4) represents 
around 1% of the total cell suspension, the G-R+ population (gate P5) represents 
0,3% and G+R+ population (gate P3) represents 0,2%. The same panel depicts 
a final schematic representation with colored dots identifying each of the sorted 
populations. On day 6 of differentiation the percentage of cells in each 
population did not change considerably (data not shown). To assess the purity 
of the sorted populations, the preliminary sorted cells underwent a second 
round of sorting, using the same gate settings, hence confirming the identity of 
these cells, and verifying the that the mechanical stress exerted on them during 
the sorting process, did not have a significant impact on cell viability (data not 
shown). 
 After sorting the cells, total RNA collection was performed as described before, 
and RNA quality and integrity assays were performed using the Experion™ 
automated electrophoresis chips. This procedure is a crucial step in the 
isolation of mRNA for further sequencing analysis, since it detects potential 
contamination of our sample with ribosomal RNA (rRNA) and genomic DNA. 
During the electrophoresis the separation generates a broad mRNA peak, and 
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any contaminating rRNA peaks will be visible. rRNA peaks and RNA ratios, 
such as the ratio of the two large ribosomal RNA molecules (28S/18S rRNA), 
are calculated for total RNA samples providing a measure of RNA degradation 
since the 28S rRNA is more susceptible to degradation than the 18S fragment. 
An intact RNA sample has a 18S:28S ratio of around 2.0. In this analysis the 
results are displayed in an electropherogram and simulated gel view, which 
indicates if the sample has been degraded and if it contains genomic DNA or 
rRNA contaminations. The combination of these two parameters gives an RQI 
 
Figure 4.1 – Gate settings used for ESC-derived cardiac progenitor cell sorting. 
The upper left panel shows cell complexity and viability, which was taken into 
account to set the scatter gate P1. The upper right panel shows the gate settings 
established for the cell sorting used in our experiment, as described in the literature, 
here exemplified by one of the replicates from day 4 of differentiation. The red 
fluorescence is represented on the y-axis and the green fluorescence is represented 
on the x-axis. Both axes are in Logicle (bi-exponential) scale. Colored dots are 
represented as a visual aid to highlight each of the populations sorted, where the 
blue dots from P2 correspond to the G-R- population, the yellow P3 dots correspond 
to the G+R+ population, the P4 green dots, correspond to the G+R- population and the 
red P5 dots correspond to the G-R+ population. The two lower panels show a 
retrospective analysis of the FACS data of our cell sorting experiments, displaying a 
different visualization of the cell population density (left panel corresponds to day 4 of 
differentiation, and right corresponds to day 6 of differentiation). Gates P2’-P5’ show 
the optimal settings to accurately sort the cell populations de facto present in our 
sample. 
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score with optimal values varying between 8-10. Figure 4.2 shows an example 
of such analysis in one RNA sample isolated from one of the sorted cell 
populations, indicating that no contaminants with DNA or rRNA were present. A 
RQI value of 9.9 was obtained for this sample indicating a biological material of 
excellent quality. The results for this sample are representative of all the 18 
samples collected for RNA sequencing. In total 500ng of each RNA sample 
were used for sequencing. Please note that one of the replicates of the G+R+ 
population at day 6 was not sequenced since the RNA got degraded during its 
transportation to the sequencing lab located in Finland. 
RNA sequence data quality analysis 
The first step of RNAseq data analysis is checking the quality of the resulting 
dataset. There are several quality metrics that are routinely used, from which 
we chose two of the most informative ones: (i) hierarchical clustering of the 
samples (Figure 4.) and (ii) the distribution of the expression values (Figure 
4.4). When we cluster the expression values for all mapped reads (mapped 
reads are the ones that confidently align to the mouse genome), we obtain the  
 
Figure 4.2 - Integrity and quality analysis of a representative RNA sample from 
the cell populations isolated by FACS. In (A) the RNA sample 1 does not contain 
any contaminations with genomic DNA nor with rRNA, and it kept its integrity, i.e. it is 
not degraded. In (B) the ratio between the18S and 28S peaks from sample 1 shows a 
good RQI value of 9.9. This indicates that the sample is of excellent quality and can 
proceed to RNA sequencing. 
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dendrogram shown in Figure 4., containing three main clusters corresponding to 
a separation of the samples according to time of differentiation. Noteworthy is 
the fact that replicate 1 from the G-R+ sample for day 6 clusters outside all other 
samples, suggesting that the values of expression measured for this replicate 
are significantly different from its replicate (RedDay6_0). Here, we hypothesize 
that this difference is due to the fact that the RNA from this sample was 
extracted via a different protocol (trizol). Additionally, for each time point we 
 
Figure 4.3 – Hierarchical clustering of the expression of all genes (showing the 
replicates). When we cluster the expression values for the mapped reads we obtain 
the following dendrogram where we can see that there are three main clusters 
separating the samples time wise. Noteworthy is the fact that the replicate sample for 
red day 6 clusters outside hinting that the values of expression measured are 
significantly different from its replicate. Since the RNA from this sample was extracted 
via a different protocol (trizol) we hypothesize that this fact explains this observation.  
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observe a tendency for all cell populations from the same biological replicate to 
cluster together instead of clustering with its population replicate. This suggests 
that the cell populations from the same differentiation assay are more similar 
between themselves, than they are between the same population from the other 
biological differentiation replicate. Accordingly, this hierarchical clustering 
analysis shows that time is the most significant variable in our experimental 
setting, i.e. time of differentiation explains most of the variability, while the 
subpopulations of cardiac progenitors is a secondary variable.  
Figure 4.4 shows the distribution of the gene expression values in each 
population evaluated. As expected, the normalization procedure has generated 
samples with very similar distributions. However, the RedDay6 sample 
distribution shows a significantly different median, as highlighted by the red 
visual aid line. This observation corroborates the results from the hierarchical 
clustering analysis, which shows its replicate 1 clustering outside the main 
 
Figure 4.4 – Boxplot displaying the distribution of the expression values of the 
samples from our dataset. The distribution is similar between all samples. As 
highlighted by the red visual aid line, we can see that the median of the RedDay6 
population deviates from those of the other populations, corroborating what was 
observed in the clustering shown in the previous figure for its replicate number 1 
(RedDay6_1). 
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cluster. 
As aforementioned, the preliminary analysis has shown that the individual cell 
populations were not clustering together (only time was effectively clustering the 
samples). Accordingly, to investigate the pureness of these cell populations we 
decided to verify the accuracy of the FAC Sorting by counting the total number 
of dsRed and eGFP transcripts present in the RNA-seq dataset. These results 
(Figure 4.) unequivocally show that there is no pure G-R+ populations in our 
samples. Consequently, downstream analysis were conducted exclusively using 
the populations for which there were congruent results, namely the populations 
G+R-   at day 4 of differentiation and G+R-, G+R+ at day 6 of differentiation.  
Identification and functional network analysis of differentially expressed 
genes in different cardiac progenitor populations 
To identify the genes differentially expressed in our cardiac progenitor 
populations (G+R- day 4 and G+R-, G+R+ day 6) we used as baseline the 
 
Figure 4.5 – Absolute dsRed and eGFP transcripts count from RNA-seq dataset. 
Counting the number of dsRed and eGFP transcripts present in each sorted population 
let us investigate its pureness. The numbers unequivocally show that there are no pure 
red populations at days 4 and 6 of differentiation. Also, although the number of eGFP 
transcripts in the G+R- population at day 6 is high, dsRed transcripts seem to be also 
very enriched leading us to hypothesize that this population could be in fact G+R+*. 
Please note that the number of counts is absolute for each sample, directly depending 
on the number of cells sorted. This means that comparisons are only meaningful 
between red and green counts within the same sample, but not between the different 
samples. 
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expression levels of the control population G-R- for the corresponding 
differentiation day. The results are summarized in two different Venn diagrams: 
Figure 4.6 uses G-R- day 4 as baseline, and Figure 4.7 uses G-R- day 6 as 
baseline. These show the results from the intersections obtained from the set of 
exclusive genes up-regulated in the “all versus all" population analysis. These 
sets of genes represent the unique genetic signature of each sorted population, 
since all genes present in more than one comparison were excluded. The 
supplementary Table 4.4 - 4.6 in annex, present the full lists containing the 
genes that are exclusively up-regulated in each population. Table 4.4 shows the 
gene that is up-regulated in the G+R- population at day 4; Table 4.5 contains the 
genes up-regulated in the G+R- population at day 6; and Table 4.6 lists the 
genes up-regulated in the G+R+ population at day 6. This approach identified the 
exclusive set of up-regulated genes for each cell population (when compared to 
the control double negative population). Subsequently, we proceeded with the 
annotation of these genes, namely by finding (1) its attributed molecular 
functions (if any) described in public databases, (2) the biological processes 
they are involved in, and (3) the potential functional pathways where they play a 
role. After the annotation, we performed functional enrichment analysis on our 
gene lists in order to investigate the presence of functions enriched in our gene 
lists, i.e. to discover which biological functions and/or pathways are common to 
sub-groups of genes in our lists. For that, we used the online tool DAVID 
(http://david.abcc.ncifcrf.gov), using its resources to query the KEGG Pathway 
database (http://www.kegg.jp) and the Gene Ontology (GO) 
(http://www.geneontology.org) Biological Process and Molecular Function 
databases.  
When looking at the G+R- population at day 4 we can identify only one exclusive 
gene - March6 - whose expression is up-regulated when compared to the 
baseline expression values of the G-R- population on the same day of 
differentiation (Table 4.4). Interestingly this gene has not been associated with 
any cardiac function. In the G+R- population at day 6 of differentiation one can 
identify 75 genes exclusively up-regulated compared to the baseline expression 
of the control population from the same day of differentiation.  
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Figure 4.6 – Venn diagram highlighting the number of genes exclusively up-
regulated in the G+R- population at day 4 of differentiation. Only gene March6 is 
exclusively up-regulated in the G+R- population at day 4 of differentiation, using as 
baseline the values of the control population from the same day of differentiation. 
 
 
 
Figure 4.7 – Venn diagram highlighting the number of genes exclusively up-
regulated in the G+R- and G+R+ populations at day 6 of differentiation. As 
depicted in this scheme there are 75 exclusive genes up-regulated in the G+R- 
population and 26 exclusive genes up-regulated in the G+R+ population at day 6 of 
differentiation, using as baseline the values of the control population from the same 
day of differentiation in both cases. 
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Through functional enrichment analysis the clusters with better q-value (which is 
the p-value adjusted for multiple testing) grouped several of these genes as 
being involved in cardiac functions. Table 4.2 shows the top 5 results for 
enriched biological functions in our gene list from the green day6 population. 
Accordingly, (1) heart development tops the list with 15 out of the 75 genes, i.e. 
19,7% of the genes, followed by (2) cardiac muscle contraction with 10 genes, 
(3) hypertrophic cardiomyopathy with 10 genes, (4) myofibril assembly with 7 
genes and (5) dilated cardiomyopathy with 10 genes. Figure 4.8 represents the 
cardiac muscle contraction pathway, which is the most significant biological 
process, grouping 10 genes from our list. Interestingly, among the 75 up-
regulated genes we can identify Nkx2.5, corroborating the cardiac identity of 
these cells. Hence these results are the proof of principle that we were able to 
sort a population of cells with enriched cardiac biological functions. However we 
can also identify Mef2c as being up-regulated in this population of cells, which is 
consistent with the presence of dsRed transcripts described in Figure 4.. This 
suggests that this population of cells is not exclusively Nkx2.5+ FHF progenitors 
but rather a mixture with double positive Nkx2.5+/Mef2c+ SHF progenitors, i.e. 
G+R- with G+R+. 
Database Term #genes %genes p-value q-value 
GO-BP Heart development 15 19,7 2.0E-14 2.8E-11 
KP Cardiac muscle contraction 10 13,2 5.6E-10 1.5E-8 
KP Hypertrophic cardiomyopathy 10 13,2 5.6E-10 2.9E-8 
GO-BP Myofibril assembly 7 9,2 7.8E-9 5.2E-8 
KP Dilated cardiomyopathy 10 13,2 8.6E-10 6.8E-8 
Table 4.2 – List of enriched biological functions found in the up-regulated gene list 
exclusively from the G+R-population at day 6 of differentiation. GO-BP: Gene Ontology 
Biological Process; KP: KEGG Pathway. 
Database Term #genes %genes p-value q-value 
GO-MF Carbohydrate binding 5 20 0,00164 0,0537 
Table 4.1 – List of enriched biological functions found in the up-regulated exclusive 
genes from the G+R+population at day 6 of differentiation. GO-MF: Gene Ontology 
Molecular Function. 
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The same enrichment analysis was applied to investigate the functional 
annotation of the 26 genes exclusively up-regulated in the G+R+ population of 
cells at day 6 of differentiation. Contrasting with the previous results, none of 
these genes are significantly associated with a cardiac biological function. 
Interestingly, Table 4.1 lists carbohydrate binding as the only biological process 
found to be enriched in this gene list, grouping 5 of the identified genes, 
however with no statistical significance (q-value = 0,0537).  
Given that the main aim of this study was the identification of novel genes 
potentially involved in cardiogenesis, it was important to isolate from 
differentiating mouse ESCs different populations of cardiac progenitor cells. 
Regarding the G+R+ population at day 6 of differentiation, on the one hand we 
can identify the presence of dsRed and eGFP transcripts in this population 
 
Figure 4.8 – Cardiac Muscle Contraction pathway, which is significantly enriched 
in the list of up-regulated genes in the G+R- population at day 6 of differentiation. 
The Cardiac Muscle Contraction is one of the biological processes which groups 13,2% 
of the genes present in our list. The red stars highlight the genes from our list, most 
notably TnC and TnT. Scheme retrieved from the KEGG Pathway database.  
 
 
  Chapter IV – Novel cardiac genetic players 
 
81 
 
(Figure 4.5), but on the other hand neither Nkx2.5 or Mef2c are found to be 
significantly up-regulated when compared to the control population, suggesting 
that these cells cannot be considered SHF progenitors. Indeed, the fact that all 
the significantly up-regulated genes do not have any cardiac functional 
annotation is consistent with this population not being representative of a 
cardiac progenitor population.  
The G+R- population at day 4 of differentiation displays the same pattern, since 
there is a lack of up-regulated Nkx2.5 and the only gene that is found to be 
significantly up-regulated is not annotated to have a cardiac function.  
These findings led us to focus further analyses solely on the dataset 
corresponding to the G+R- population from day 6 of differentiation, which shows 
strong association with cardiac development, despite, as mentioned before it 
being most likely composed of a mixed population of cardiac progenitors. 
Pre-validation of exclusively up-regulated candidate genes in the G+R- 
population at day 6 of differentiation  
The detailed analysis of the up-regulated genes in the G+R- population from day 
6 of differentiation showed 71 genes with known functional annotation, of which 
49 are present in the Gene Ontology Biological Process (GO-BP) database. As 
aforementioned in Table 4.1 the biological process with best enrichment score 
is "Heart Development". Accordingly, when one analyses the overall biological 
processes to which the genes are associated, the results seem consistent with 
this finding, where 37 out of the total 75 genes are annotated to be involved in 
at least one of the following processes: cardiac or heart development, muscle 
development, blood and vasculature development and ion transport. From all 
the other genes with no association with any of these processes, we selected a 
number of candidates for experimental validation by prioritizing the gene list 
using the following criteria: log 2 fold change expression above 3, q-value below 
0.05, and relevant molecular function keywords. The resulting candidate gene 
list is presented on Table 4.3. Next, we engaged in verifying which of these 
genes had published expression patterns either by RNA in situ hybridization 
and other RNA expression data. This analysis yielded relevant data for Asb2, 
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Cck and 3632451O06Rik, whose functions are highlighted in the following 
paragraphs. 
 According to the Genecards database, Asb2 encodes a protein member of the 
ankyrin repeat and SOCS box-containing (ASB) family, which has a role in 
protein degradation by coupling suppressor-of-cytokine-signalling (SOCS) 
proteins with the elongin BC complex. Functionally it is associated to retinoic 
acid-induced growth inhibition and differentiation of myeloid leukemia cells. This 
gene presents several alternatively spliced transcript variants, encoding multiple 
isoforms. Despite the fact that no function as yet been associated with cardiac 
development, its expression can be transiently found in mouse embryonic 
hearts at E9.5-10.5 (Terami et al., 2007). Accordingly, in the Genecards 
database is found RNA expression data for this gene with enriched expression 
in human heart and muscle tissues. 
Cck is a gene which encodes for cholecystokinin, which is a neuropeptide 
secreted by intestinal cells and neurons in response to a meal. It acts as a gut 
hormone that regulates pancreatic enzyme secretion and gastrointestinal 
motility, and modulating the satiety signal. It can be cleaved in a variety of 
biologically active forms including CCK-33, CCK-8 (CCK octapeptide), CCK-39 
and CCK-58. Its expression in the developing mouse embryo can be found as 
early as of E11.5 in the brain, however its physiological role is yet unknown 
(Giacobini et al., 2008). Interestingly, even though the available RNA in situ 
Gene log2 fold change p-value q-value Function Keywords 
Asb2 5,30441 5,65283 5,00E-05 Proteolysis 
Rpph1 4,8952 4,48402 5,00E-05 N/A 
Cck 4,14957 3,42346 1,00E-04 Secreted hormone 
Lca5l 3,41157 4,1799 5,00E-05 Coiled coil 
Diras2 3,37906 3,86454 5,00E-05 Membrane associated 
Synpo2l 3,13446 4,04153 5,00E-05 Protein binding 
Lad1 3,08541 2,61011 5,00E-05 Extracellular matrix 
3632451O06Rik 2,12134 3,05876 0,00015 Transmembrane 
Table 4.3 – List of candidate genes selected from the  significantly up-regulated genes in 
G+R- population at day 6 of differentiation, with log 2 fold change above 3 and not 
associated with cardiac, vascular or muscle development 
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data does not identify its expression in the developing heart region, RNA-seq 
data found on the Genecards database, shows that it is expressed in human 
heart and skeletal muscle, consistent with our findings of being enriched in 
ESC-derived cardiac progenitor cells.  
We also selected the gene 3632451O06Rik as a very promising candidate to 
study since it encodes an uncharacterized protein, with a strong expression in 
the developing heart at E9.5 – 10.5 (Terami et al., 2007), whose potential role in 
cardiogenesis has never been identified. One of its features is that the protein 
has a transmembrane and extracellular domain that could be very promising as 
a biomarker, enabling the isolation of cardiac progenitor cells. 
For the other genes present in Table 4.4, the available data is not clear 
regarding its expression in the developing heart. Nonetheless, to validate 
whether any of these genes, including Asb2, Cck and 3632451O06Rik have 
specific roles in early cardiogenesis, functional in vitro and in vivo analysis are 
required. The first approach would be the experimental quantitative PCR 
validation of its expression levels in embryonic hearts and cardiac progenitor 
cells. Henceforth one could engage in developing loss and gain of function 
assays to modulate the gene expression in these models, clarifying their 
potential involvement in cardiogenesis. 
 
4.4. DISCUSSION AND CONCLUSION 
It is a primary goal for translational medicine applications to improve the use of 
the genetic properties that characterize specific cell types found in the human 
body. One efficient and high-throughput approach to do so is by performing 
genome-wide analysis for the fast identification of genetic signatures of some of 
these cells. This technology intends in part to ease the isolation of specific cell 
populations that can be used for transplantation in patients and disease 
treatments. 
In our analysis we aimed at investigating some of the genetic networks 
underlying embryonic cardiogenesis to identify novel genes or isoforms 
potentially involved in this important developmental process. By using a double 
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transgenic ESCs line we prompted to isolate ESC-derived FHF and SHF 
cardiac progenitors at days 4 and 6 of differentiation, at which a whole 
transcriptome analysis was performed to assess the expression of all genes 
and find potentially novel genetic players involved. 
One major goal of this task was to probe the existence of a genetic signature 
that characterizes the different populations of cardiac progenitor cells at 
different time points. From the quality control analysis performed on our RNA-
seq dataset, the hierarchical clustering grouped all the isolated cell populations 
in three major branches, separated time wise (Figure 4.3). Since the ESCs 
differentiation seems to recapitulate the early steps of in vivo developmental 
processes, these results might be related to the fact that during development 
many genes have a short and specific time window of expression. Additionally, 
the fact that the lineages’ replicates do not cluster together suggests that the 
difference between lineages is very subtle and not fully grasped by an overall 
clustering analysis. However, when we were led to count the number of dsRed 
and eGFP transcripts (Figure 4.5) in the G-R+ population at day 6 due to its 
contrasting clustering, we could unequivocally confirm that there was not a pure 
red population in our samples. This prompted us to retrospectively analyze the 
data collected from the sorting experiments. From this analysis one can contrast 
the gates de facto used for cell sorting in the upper right panel of Figure 4.1 
(P2-P5) with the gates that could have been applied to sort the cells (bottom 
two panels of Figure4.1 gates P2’-P5’). This ‘logicle’ representation follows the 
recommendations found in the literature (Herzenberg et al., 2006) and enables 
the user to objectively detect the presence of different cell populations within a 
sample. By doing so it allows the collection gates to be set around the cell 
population mass centre, discarding the probability of collecting rather mixed cell 
populations. Indeed, this representation clearly does not detect the existence of 
a pure G-R+ either at days 4 or 6 of ESCs differentiation as we do not observe 
the presence of a strong cell population on gate P5’. The discrepancies found in 
setting the sorting gates help to explain the fact that we cannot detect higher 
number of exclusively enriched expressed genes in each of the sorted 
populations, as most likely, the populations were not pure.  
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However it is now clear how these limitations on the FAC Sorting step have 
impacted our results. However, our analyses delivered a set of up-regulated 
genes enriched for development and cardiac functions in the mixed cell 
population of FHF and SHF isolated at day 6 of differentiation. This clearly 
corroborates their cardiac identity as many of the up-regulated genes are key 
cardiac transcription factors such as Nkx2.5, Mef2c, Myocd, Lbh, Csrp3 and 
Smyd1 (Table 4.5). At the same time, a set of candidate genes with no known 
cardiac annotation was also identified with having up-regulated expression in 
these ESC-derived cardiac progenitors, of which the most interesting are found 
in Table 4.3. Remarkably, when searching for gene expression data for our 
candidate genes in the literature and on the available databases, we found that 
screening experiments performed by independent labs, had identified some of 
our selected genes to be enriched in other populations of ESC-derived cardiac 
cells. For example, Terami and colleagues had previously identified through 
microarrays Nebl, Asb2, Diras2, 3632451O06Rik, Rcsd1 and Popdc2 to be 
richly expressed in ESC-derived cardiomyocytes (Terami et al., 2007). In this 
experiment the authors used a transgenic Nkx2.5/eGFP mouse ESC line, from 
which they isolated cardiomyocytes from differentiating EBs and searched for 
cardiogenesis-associated genes. In agreement with this approach we were also 
able to detect by RNA-seq – a more recent technology for whole-transcriptome 
screening analysis – some of the genes they have highlighted as interesting. 
Moreover, we detected significant differential expression for 3 potentially novel 
cardiogenesis-associated genes, namely Asb2, Cck and 3632451O06Rik. 
These candidates hold great promise, and their functional involvement in 
cardiogenesis should be further investigated experimentally. 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Due to the complexity of heart disease and to its increasing incidence and 
prevalence in developed countries, it is urgent to fully understand all the 
molecular pathways involved in heart development in order to generate effective 
therapies. The scope of the present work aimed at exploring the role of Ccbe1 
in cardiac differentiation of mouse ESCs. The investigation of the role of Ccbe1 
had been mainly focusing on lymphangiogenesis, but a possible role in 
cardiogenesis deserved further investigation. A report from our lab has 
described that Ccbe1 is expressed in the early cardiogenic fields of the 
developing heart in mouse embryos as early as E7.0 (Facucho-Oliveira et al., 
2011). Later, we demonstrated that modulating Ccbe1 expression in chicken 
embryos led to incorrect fusion of the developing heart tube, which was 
incompatible with life due to the severity of the resulting defects (Furtado et al., 
2014). These data are in agreement with what has been described in some HS 
patients, which show congenital heart defects including hypertrophic 
cardiomyopathy and ventricular septal defects (Alders et al., 2009; Connell et 
al., 2010; Frosk et al., 2015). This syndrome is however caused by different 
mutations in the human CCBE1 gene, which may have different impact on the 
function of the protein and therefore be compatible with life. Moreover, CCBE1 
was found to interact with proteins with no associated function in 
lymphangiogenesis, suggesting additional roles in other biological processes 
(Jeltsch et al., 2014). Here, we demonstrated that Ccbe1 is required for the 
early cardiac commitment of differentiating mouse ESCs.  
As described earlier, a report from our lab has associated CCBE1 with cell 
proliferation on cardiac progenitors during avian heart development. In this 
study, our lab has shown that CCBE1 morphants present a decreased 
proliferation rate in the splanchnic and pharyngeal mesoderm regions (Furtado 
et al., 2014). Other experiments performed in our lab using MEFs isolated from 
KO Ccbe1 embryos revealed that the disruption of this gene also leads to a 
decrease in the proliferation when compared to MEFs isolated from wild type 
littermates (unpublished data). In line with this, one of the defects that stood out 
during the differentiation of the generated Ccbe1 KD ESCs lines presented 
here, besides the impaired commitment of differentiating ESCs in cardiac 
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mesoderm progenitors, was a strikingly reduced proliferation of the 
differentiating cells leading to smaller EBs. At first, this proliferation defect could 
not be clearly dissociated from being the cause of the impairment in cardiac 
mesoderm formation, but experiments with supplementation of Ccbe1 blocking 
antibody and recombinant CCBE1 suggested that these defects are 
independent from each other. Indeed, supplementing differentiating WT EBs 
with α-Ccbe1 antibody led to a clear reduction in the expression of cardiac 
mesoderm markers at day 4 of differentiation, even though the size of the EBs 
was preserved. In contrast, when supplementing the differentiating Ccbe1 KD 
ESCs lines with recombinant CCBE1, we were able to partially rescue the size 
of the KD EBs, but the expression of the cardiac mesoderm markers remained 
downregulated. These data suggest that those defects are independent from 
each other, but are intimately related to the disruption of Ccbe1, placing CCBE1 
as a direct regulator of cell proliferation and cardiac mesoderm specification 
during ESC differentiation.  
As mentioned above, supplementation of recombinant CCBE1 in differentiating 
Ccbe1 KD lines was unable to rescue the expression of the cardiac markers 
Mesp1 and Isl1, but could partially rescue the size of the EBs. This may 
perhaps be explained by the fact that the concentrations of purified human 
recombinant CCBE1 that were supplemented were too low, or even that the 
purified protein was not fully functional. This latter hypothesis brings to light 
some of the possible limitations that are presently being optimized on the 
CCBE1 protein production and purification protocols. One big challenge of 
working with uncharacterized proteins is that it is hard to establish functional 
assays to assure both the quality and functionality of the produced protein. This 
may be major limitation as it could result that dysfunctional forms of a protein 
are being used in experimental assays and lead to false negative or biased 
results. In this particular case of the CCBE1 protein, a recent report showing a 
physical interaction with ADAMTS3, leading to the processing of pro-VEGF-C in 
VEGF-C, was a major breakthrough (Jeltsch et al., 2014). This knowledge will 
allow now the development of functional assays that will serve as optimal 
functional assays and quality controls in the production of functional CCBE1 
protein. Nonetheless, prior to these recent advances, we used the Ccbe1 KD 
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ESCs clones to supplement with the purified CCBE1 protein produced by our 
lab, to assess if the purified protein was functional and could rescue the 
phenotypes caused by the absence of Ccbe1. As aforementioned, the protein 
was able to partially rescue the phenotype caused by the absence of Ccbe1, 
suggesting that the purified protein preserved its function at least to some 
extent. Another challenge related to the production of proteins is the choice of 
appropriate production systems, i.e. cell types and culture protocols, which will 
meet the requisites allowing all needed post-translation modifications on the 
produced proteins. Indeed, post-translation modifications such as glycosylation 
or enzymatic processing are known to affect the function of the proteins 
(Parekh, 1991; Creighton, 1993), and as predicted for the mouse and human 
CCBE1 forms (Figure 1.), there are two different glycosylation sites. Therefore, 
it is possible that if the purified CCBE1 lacks the normal glycosylation pattern its 
function can be somewhat affected. Alternatively, since it has been suggested 
that CCBE1 can be proteolytically processed by ADAMTS3 (Jeltsch et al., 
2014), it is possible that the full length protein that we provided to the 
differentiating ESCs still had to be processed, or cleaved to become fully active, 
and consequently rescue all the resulting defects caused by the disruption of 
Ccbe1.  
Despite the protein production limitations discussed above, the production and 
purification of the full recombinant human CCBE1 obtained for this work set 
unprecedented advances in the study of the function of this protein. So far, the 
literature involving the production and use of CCBE1 protein had stressed many 
limitations on the production and purification protocols (Bos et al., 2011) This 
led to the production and analysis in an lymphangiogenesis assay of a 
truncanted form of CCBE1 that lacks the collagen domains (Bos et al., 2011), 
which have recently been shown to be absolutely pivotal during 
lymphangiogenesis (Roukens et al., 2015). Generation of mutant mice and 
zebrafish with targeted deletions of the different predicted functional domains of 
CCBE1, actually allowed to discriminate the roles of the different domains of the 
CCBE1 protein during lymphangiogenesis (Roukens et al., 2015). Nonetheless, 
final protocol optimizations and scaling-up the production and purification of 
CCBE1 in our lab, will allow us to take even further the study of this protein. For 
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example, it will possibly allow us to determine the role of the full-length protein 
as an ECM component, the mechanisms underlying its involvement on cell 
proliferation and, more interestingly, its potential as a cardiogenic inducing 
factor during ESC differentiation.  
The in vitro experiments performed throughout this work highlighted the need of 
Ccbe1 during early stages of cardiac commitment from differentiating ESCs. 
With impaired formation of early cardiac mesoderm progenitors upon 
constitutive KD of Ccbe1, it becomes impossible to determine the role of Ccbe1 
at the later stages of cardiac differentiation using this model. As described in the 
literature, however, Ccbe1 is expressed at later stages of mammalian cardiac 
development (Facucho-Oliveira et al., 2011), and both chicken embryos and HS 
patients present cardiac defects upon disruption of CCBE1 (Alders et al., 2009; 
Connell et al., 2010; Connell et al., 2012; Furtado et al., 2014). This is a strong 
indication that Ccbe1 has a role at later stages of cardiogenesis. To study this 
possible role of Ccbe1 at later stages of ESCs cardiac differentiation, we could 
e.g. generate ESCs lines that would allow the disruption of this gene at specific 
time points during ESC differentiation. One way of doing this could be by 
generating inducible Ccbe1 KD ESCs lines. This would allow us to understand 
whether Ccbe1 affects the full maturation in vitro of existing cardiac progenitors 
and/or beating cardiomyocytes past its role in cardiac mesoderm formation.  
From the analysis of our data, we postulated that the role of CCBE1 during 
cardiac commitment of differentiating ESCs seems to be independent of its 
known function in promoting the maturation of pro-VEGF-C. This brings into 
perspective a whole new set of possible signaling pathways being activated and 
working together with CCBE1 to promote cardiac mesoderm formation. 
However, whether during cardiac differentiation CCBE1 acts alone or has other 
interacting partners that function to promote cardiac mesoderm formation 
remains unknown. Moreover, it is also not understood how the downregulation 
of Ccbe1 affects the expression of Vegf-C itself. To address these questions it 
would be interesting to perform a co-immunoprecipitation assay to identify novel 
interacting partners for CCBE1 to better understand what other signaling 
pathways or signaling partners couple with CCBE1 in the cardiac commitment 
context.  
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Ultimately, the goal of our lab is to understand if CCBE1 could be used to 
promote cardiomyocyte commitment from differentiating ESCs, to use them in 
the context of regenerating myocardial tissue. The use of cardiomyocytes as a 
source of cells for transplantation to regenerate damaged tissue is reaching 
unprecedented potential. However, to keep growing this potential it is necessary 
to create and optimize safe and ethically acceptable protocols to produce large-
scale human mature cardiomyocytes. Ideally, genetic manipulation of the 
implanted cells should be avoided, and the best alternative is to use secreted 
factors that are able to effectively drive cardiomyocyte differentiation form 
ESCs.  CCBE1 is a secreted protein, which makes it an interesting candidate to 
study. To test whether CCBE1 promotes cardiomyocyte commitment, we could 
generate an ESC line with inducible Ccbe1 overexpression to evaluate the 
effects of Ccbe1 gain-of-function. In contrast to the experiments with the 
supplementation of recombinant CCBE1, this strategy could possibly 
circumvent any dosage limitations as we would have CCBE1 being directly 
overexpressed by the differentiating ESCs. 
One big limitation of using cell-based therapies in cardiovascular regenerative 
medicine is the lack of a long-lasting homing of the cells on the injured areas 
(Taghavi and George, 2013). However, recent developments on the use of such 
therapies have shown that pre-treating cells with several factors prior to their 
transplantation can greatly improve the cell-homing to the injured areas, 
therefore enhancing their therapeutic efficacy. One of such factors is Col IV 
which is shown to extend the paracrine beneficial effects of the transplanted 
cells and to help the maturation of the transplanted PSCs into cardiomyocytes 
(Li et al., 2015). Another factor, identified as Ro-31-8425, is shown to increase 
firm adhesion to intercellular adhesion molecule 1 (ICAM-1) enabling targeted 
delivery of systemically infused cells to the injured areas (Levy et al., 2015). 
Together, these advances may improve the clinical outcomes of cell-based 
therapies. Whether CCBE1 could also act as well as such a molecule is 
unknown and hence it would be of great interest to explore this matter further.  
Other promising breakthroughs in this field are related to long term culture of 
PSCs-derived cardiomyocytes. Indeed a report from Lundy and colleagues 
shows how maintaining long term cultures of cardiomyocytes derived from 
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PSCs contributes to the acquisition of an adult-like cardiomyocyte phenotype 
due to the structural and contractile changes that these cells undergo using 
their protocols (Lundy et al., 2014). To be able to control cardiac commitment 
from different PSC sources and to use fully mature cardiac committed cells in 
the context of regenerative medicine it is pivotal that key growth and 
cardiogenic factors are identified and studied. Differential screenings are a 
valuable tool for the identification of potentially important genes required for the 
correct development of the cardiac lineages. Ccbe1 was one of such genes, but 
there are still other recently identified gene candidates that also seem to be very 
promising, like Asb2, Cck and 3632451O06Rik. These candidates hold great 
promise, they have been already shown to be expressed in the heart and their 
functional involvement in cardiogenesis should be investigated further. This 
brings into consideration that more important than just identifying genes 
expressed in cardiogenic populations, is to understand and clarify how the 
different cardiogenic factors already identified interact with each other, and how 
these can be manipulated to optimize the existing protocols used to derive 
cardiac cells from PSCs, and ultimately improve the available cardiac therapies 
in the regenerative medicine. 
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Annexes 
Table 4.4 - The only up-regulated exclusive gene in the G+R- cardiac progenitor 
population at day 4 of differentiation, using as baseline the gene expression values of 
the G-R- population at day 4. 
Official Gene 
Symbol 
Name 
March6 SPHK1 interactor, AKAP domain containing 
 
Table 4.5 – List of up-regulated exclusive genes in the G+R- cardiac progenitor 
population at day 6 of differentiation, using as baseline the gene expression values of 
the G-R- population at day 6. 
Official Gene 
Symbol 
Name 
Sphkap SPHK1 interactor, AKAP domain containing 
Klhl30 kelch-like 30 (Drosophila) 
Rpph1 
ribonuclease P RNA-like 3; ribonuclease P RNA component H1; 
ribonuclease P RNA-like 2; predicted gene 6093 
Lbh limb-bud and heart 
Erbb4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 
Amph amphiphysin 
Plcxd3 
phosphatidylinositol-specific phospholipase C, X domain containing 
3 
Hspb7 heat shock protein family, member 7 (cardiovascular) 
Sh3bgr 
similar to putative SH3BGR protein; SH3-binding domain glutamic 
acid-rich protein 
Nrxn3 neurexin III 
Ap1s2 adaptor-related protein complex 1, sigma 2 subunit 
Nebl nebulette 
Tnnt2 troponin T2, cardiac 
Synpo2l synaptopodin 2-like 
Cdkn1c cyclin-dependent kinase inhibitor 1C (P57) 
Lca5l Leber congenital amaurosis 5-like 
Myom1 myomesin 1 
Ccnd2 cyclin D2 
Mef2c myocyte enhancer factor 2C 
Myot myotilin 
Popdc2 popeye domain containing 2 
Mybpc3 myosin binding protein C, cardiac 
Ppargc1a 
peroxisome proliferative activated receptor, gamma, coactivator 1 
alpha 
Smpx small muscle protein, X-linked 
Gyg glycogenin 
Diras2 DIRAS family, GTP-binding RAS-like 2 
Vcan versican 
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Akap2 A kinase (PRKA) anchor protein 2; paralemmin 2 
Palm2 A kinase (PRKA) anchor protein 2; paralemmin 2 
Myocd myocardin 
Myl7 myosin, light polypeptide 7, regulatory 
Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta 
Rcsd1 RCSD domain containing 1 
Ldb3 LIM domain binding 3 
Med12l 
mediator of RNA polymerase II transcription, subunit 12 homolog 
(yeast)-like 
3632451O06Rik RIKEN cDNA 3632451O06 gene 
Actn2 actinin alpha 2 
8430429K09Rik RIKEN cDNA 8430429K09 gene 
Tcap titin-cap 
Xirp1 xin actin-binding repeat containing 1 
Lad1 ladinin 
Cox6a2 cytochrome c oxidase, subunit VI a, polypeptide 2 
Asb2 ankyrin repeat and SOCS box-containing 2 
Hspb3 heat shock protein 3 
Nkx2-5 NK2 transcription factor related, locus 5 (Drosophila) 
Filip1 filamin A interacting protein 1 
Smyd1 SET and MYND domain containing 1 
Myl3 myosin, light polypeptide 3 
Trpc7 transient receptor potential cation channel, subfamily C, member 7 
Kcnh7 
potassium voltage-gated channel, subfamily H (eag-related), 
member 7 
Cck cholecystokinin 
Cpeb2 cytoplasmic polyadenylation element binding protein 2 
Tnni1 troponin I, skeletal, slow 1 
Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) 
Rhoj ras homolog gene family, member J 
Clec9a C-type lectin domain family 9, member a 
Sh2d2a SH2 domain protein 2A 
Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 
Prkg1 protein kinase, cGMP-dependent, type I 
Unc45b unc-45 homolog B (C. elegans) 
Cdh5 cadherin 5 
Lmod1 leiomodin 1 (smooth muscle) 
Myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha 
Trim55 tripartite motif-containing 55 
Tnnc1 troponin C, cardiac/slow skeletal 
Gm5779 predicted gene 5779 
Csrp3 cysteine and glycine-rich protein 3 
Rbm24 RNA binding motif protein 24 
Actc1 actin, alpha, cardiac muscle 1; similar to alpha-actin (AA 27-375) 
Jph2 junctophilin 2 
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Sox7 SRY-box containing gene 7 
Sorbs2 sorbin and SH3 domain containing 2 
Ryr2 ryanodine receptor 2, cardiac 
Gimap6 GTPase, IMAP family member 6 
Mpped2 metallophosphoesterase domain containing 2 
Myl2 myosin, light polypeptide 2, regulatory, cardiac, slow 
Car8 
carbonic anhydrase 8; similar to Carbonic anhydrase-related protein 
(CARP) (CA-VIII) 
 
Table 4.6 – List of up-regulated exclusive genes in the G+R+ cardiac progenitor 
population at day 6 of differentiation, using as baseline the gene expression values of 
the G-R- population at day 6. 
Official Gene 
Symbol 
Name 
Emp1 epithelial membrane protein 1 
Mmp3 matrix metallopeptidase 3 
Kcne4 potassium voltage-gated channel, Isk-related subfamily, gene 4 
Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 
Ptgs2 prostaglandin-endoperoxide synthase 2 
Nov nephroblastoma overexpressed gene 
Bgn biglycan 
Gpnmb glycoprotein (transmembrane) nmb 
Hoxd12 homeo box D12 
Lgals1 lectin, galactose binding, soluble 1 
Gldn gliomedin 
Serpinb2 serine (or cysteine) peptidase inhibitor, clade B, member 2 
Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 
Cp ceruloplasmin 
Agtr2 angiotensin II receptor, type 2 
Cbr2 carbonyl reductase 2 
Eif2s3y 
eukaryotic translation initiation factor 2, subunit 3, structural gene 
Y-linked 
Mmp10 matrix metallopeptidase 10 
Cpe carboxypeptidase E; similar to carboxypeptidase E 
Anxa1 annexin A1 
Col5a3 collagen, type V, alpha 3 
Inhbb inhibin beta-B 
S100a6 S100 calcium binding protein A6 (calcyclin) 
Grem1 gremlin 1 
Evx2 even skipped homeotic gene 2 homolog 
 
